0001193125-20-135312.txt : 20200507 0001193125-20-135312.hdr.sgml : 20200507 20200507060328 ACCESSION NUMBER: 0001193125-20-135312 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 20854360 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 10-Q 1 d848605d10q.htm 10-Q 10-Q
false2020Q10001157601--12-31 0001157601 2020-03-31 0001157601 2019-12-31 0001157601 2020-01-01 2020-03-31 0001157601 2019-01-01 2019-03-31 0001157601 2020-05-04 0001157601 2018-12-31 0001157601 2019-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities2Member 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities2Member 2020-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2020-03-31 0001157601 mdgl:ResearchDevelopmentAndCommercializationAgreementMember mdgl:HoffmanLaRocheMember 2020-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member us-gaap:FairValueInputsLevel2Member 2020-03-31 0001157601 mdgl:CorporateDebtSecurities3Member us-gaap:FairValueInputsLevel2Member 2020-03-31 0001157601 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member us-gaap:FairValueInputsLevel2Member 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001157601 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001157601 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001157601 srt:MaximumMember 2020-01-01 2020-03-31 0001157601 mdgl:CorporateDebtSecurities2Member 2020-01-01 2020-03-31 0001157601 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0001157601 mdgl:CorporateDebtSecurities3Member srt:MinimumMember 2020-01-01 2020-03-31 0001157601 mdgl:CorporateDebtSecurities3Member srt:MaximumMember 2020-01-01 2020-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001157601 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001157601 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001157601 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001157601 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001157601 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001157601 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities3Member 2019-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-06-30 0001157601 mdgl:CorporateDebtSecurities2Member 2019-01-01 2019-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-12-31 0001157601 mdgl:CorporateDebtSecurities3Member srt:MinimumMember 2019-01-01 2019-12-31 0001157601 mdgl:CorporateDebtSecurities3Member srt:MaximumMember 2019-01-01 2019-12-31 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-06-01 2017-06-30 0001157601 us-gaap:CommonStockMember 2019-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001157601 us-gaap:RetainedEarningsMember 2019-12-31 0001157601 us-gaap:EmployeeStockOptionMember 2019-12-31 0001157601 us-gaap:PreferredStockMember 2019-12-31 0001157601 us-gaap:CommonStockMember 2020-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001157601 us-gaap:RetainedEarningsMember 2020-03-31 0001157601 us-gaap:PreferredStockMember 2020-03-31 0001157601 us-gaap:CommonStockMember 2018-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001157601 us-gaap:RetainedEarningsMember 2018-12-31 0001157601 us-gaap:PreferredStockMember 2018-12-31 0001157601 us-gaap:CommonStockMember 2019-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001157601 us-gaap:RetainedEarningsMember 2019-03-31 0001157601 us-gaap:PreferredStockMember 2019-03-31 iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares mdgl:Vote
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM
 10-Q
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the quarterly period ended March 31, 2020
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the transition period from
                    
to
                    
Commission file number:
001-33277
 
MADRIGAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
     
Delaware
 
04-3508648
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
     
Four Tower Bridge
200 Barr Harbor Drive, Suite 200
West Conshohocken, Pennsylvania
 
19428
(Address of principal executive offices)
 
(Zip Code)
 
 
 
Registrant’s telephone number, including area code:
(267)824-2827
Former name, former address and former fiscal year, if changed since last report:
Securities registered pursuant to Section 12(b) of the Act:
         
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange 
on which registered
Common Stock, $0.0001 Par Value Per Share
 
MDGL
 
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days.    
Yes
  
☒
    No  
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).    
Yes
  
☒
    No  
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
 12b-2
of the Exchange Act.
             
Large accelerated filer
 
☒
  
Accelerated filer
 
☐
             
Non-accelerated
filer
  
☐
  
Smaller reporting company
 
☐
             
 
 
Emerging growth company
 
☐
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.     
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
 12b-2
 
of the Exchange Act).    Yes  
☐
    No  
☒
As of May 
4
, 2020, the registrant had 15,429,154 shares of common stock outstanding.
 
 
MADRIGAL PHARMACEUTICALS, INC.
TABLE OF CONTENTS
             
Item
 
Description
 
Page
 
 
Part I. Financial Information
 
 
 
Item 1.
 
 
 
1
 
 
 
 
1
 
 
 
 
2
 
 
 
 
3
 
 
 
 
4
 
 
 
 
5
 
 
 
 
6
 
Item 2.
 
 
 
12
 
Item 3.
 
 
 
16
 
Item 4.
 
 
 
17
 
 
Part II. Other Information
 
 
 
Item 1.
 
 
 
17
 
Item 1A.
 
 
 
17
 
Item 2.
 
 
 
18
 
Item 3.
 
 
 
18
 
Item 4.
 
 
 
18
 
Item 5.
 
 
 
18
 
Item 6.
 
 
 
18
 
 
 
 
20
 
 
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; in thousands, except share and per share amounts)
                 
 
March 31,
2020
 
  
December 31,
2019
 
Assets
 
 
 
  
 
 
Current assets:
   
     
 
Cash and cash equivalents
  $
66,651
    $
46,697
 
Marketable securities
   
341,859
     
392,348
 
Prepaid expenses and other current assets
   
976
     
1,152
 
                 
Total current assets
   
409,486
     
440,197
 
Property and equipment, net
   
1,373
     
1,184
 
Right-of-use
asset
    
598
     
675
  
                 
Total assets
  $
411,457
    $
442,056
 
                 
Liabilities and Stockholders’ Equity
 
 
 
  
 
 
Current liabilities:
   
     
 
Accounts payable
  $
1,115
    $
1,178
 
Accrued expenses
   
24,269
     
23,637
 
Lease liability
   
319
     
315
  
                 
Total current liabilities
   
25,703
     
25,130
 
Long term liabilities:
   
     
 
Lease liability
   
279
     
361
  
                 
Total long term liabilities
   
279
     
361
  
                 
Total liabilities
   
25,982
     
25,491
 
                 
Stockholders’ equity:
   
     
 
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2020 and December 31, 2019; 1,969,797 shares issued and outstanding at March 31, 2020 and December 31, 2019
   
—  
      
—  
  
Common stock, par value $0.0001 per share authorized: 200,000,000 at March 31, 2020 and December 31, 2019; 15,429,154 shares issued and outstanding at March 31, 2020 and December 31, 2019
    
2
     
2
 
Additional
paid-in-capital
   
644,413
     
639,567
 
Accumulated other comprehensive gain (loss)
   
415
     
216
 
Accumulated deficit
   
(259,355
 )    
(223,220
 )
                 
Total stockholders’ equity
   
385,475
     
416,565
 
                 
Total liabilities and stockholders’ equity
  $
411,457
    $
442,056
 
                 
 
 
See accompanying notes to condensed consolidated financial statements.
 
 
1
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; in thousands, except share and per share amounts)
                 
 
Three Months Ended March 31,
 
 
2020
 
  
2019
 
Revenues:
   
     
 
Total revenues
  $
—
     $
—
  
Operating expenses:
   
     
 
Research and development
   
33,400
     
12,373
 
General and administrative
   
4,605
     
5,746
 
                 
Total operating expenses
   
38,005
     
18,119
 
                 
Loss from operations
   
(38,005
 )    
(18,119
 )
Interest income
   
1,870
     
3,039
 
                 
Net loss
  $
(36,135
 )   $
(15,080
 )
                 
Net loss per common share:
   
     
 
Basic and diluted net loss per common share
  $
(2.34
 )   $
(0.98
 )
Basic and diluted weighted average number of common shares outstanding
   
15,429,154
     
15,364,465
 
 
 
See accompanying notes to condensed consolidated financial statements.
 
 
2
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited; in thousands)
                 
 
Three Months Ended March 31,
 
 
2020
 
  
2019
 
Net Loss
   
(36,135
 )   $
(15,080
 )
Other comprehensive income (loss):
   
     
 
Unrealized gain on
available-for-sale
securities
    
199
     
497
 
                 
Comprehensive loss
  $
(35,936
 )   $
(14,583
 )
                 
 
 
 
See accompanying notes to condensed consolidated financial statements.
3
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; in thousands, except share and per share amounts)
                                                                 
 
Preferred stock
 
 
Common stock
 
 
Additional
paid-in

Capital
 
 
Accumulated
other
comprehensive
income (loss)
 
 
Accumulated
deficit
 
 
Total
stockholders’
equity
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
                                                                 
Balance at December 31, 2019
 
 
1,969,797
 
 
$
 —  
 
 
 
15,429,154
 
 
$
2
 
 
$
639,567
 
 
$
216
 
 
$
(223,220
)
 
$
416,565
 
Compensation expense related to stock options for services
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
4,846
 
 
 
—  
 
 
 
—  
 
 
 
4,846
 
Unrealized gain on marketable securities
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
199
 
 
 
—  
 
 
 
199
 
Net loss
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
(36,135
)
 
 
(36,135
)
                                                                 
Balance at March 31, 2020
 
 
1,969,797
 
 
$
—  
 
 
 
15,429,154
 
 
$
2
 
 
$
644,413
 
 
$
415
 
 
$
(259,355
)
 
$
385,475
 
                                                                 
Balance at December 31, 2018
 
 
1,969,797
 
 
$
 —  
 
 
 
15,409,023
 
 
$
2
 
 
$
616,573
 
 
$
(319
)
 
$
(139,272
)
 
$
476,984
 
Exercise of common stock options
 
 
—  
 
 
 
—  
 
 
 
8,041
 
 
 
—  
 
 
 
83
 
 
 
—  
 
 
 
—  
 
 
 
83
 
Compensation expense related to stock options for services
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
6,022
 
 
 
—  
 
 
 
—  
 
 
 
6,022
 
Unrealized gain on marketable securities
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
497
 
 
 
—  
 
 
 
497
 
Net loss
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
 
 
(15,080
)
 
 
(15,080
)
                                                                 
Balance at March 31, 2019
 
 
1,969,797
 
 
$
—  
 
 
 
15,417,064
 
 
$
2
 
 
$
622,678
 
 
$
178
 
 
$
(154,352
)
 
$
468,506
 
                                                                 
 
 
 
See accompanying notes to condensed consolidated financial statements.
4
MADRIGAL PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in thousands)
                 
 
Three Months Ended
March 31,
 
 
2020
 
 
2019
 
 
Cash flows from operating activities:
   
     
 
Net loss
  $
(36,135
 )   $
(15,080
 )
Adjustments to reconcile net loss to net cash used in operating activities:
   
     
 
Stock-based compensation expense
   
4,846
     
6,022
 
Depreciation and amortization expense
   
125
     
28
 
Changes in operating assets and liabilities:
   
     
 
Prepaid expenses and other current assets
   
175
     
888
 
Accounts payable
   
(63
 )    
1,889
 
Accrued expense
   
632
     
(179
 )
Accrued interest, net of interest received on maturity of investments
   
(86
 )    
(46
 )
                 
Net cash used in operating activities
   
(30,506
 )    
(6,478
 )
                 
Cash flows from investing activities:
   
     
 
Purchases of marketable securities
   
(58,647
 )    
(173,837
 )
Sales and maturities of marketable securities
   
109,421
     
170,387
 
Purchases of property and equipment, net of disposals
   
(314
 )    
(41
 )
                 
Net cash provided by (used in) investing activities
   
50,460
     
(3,491
 )
                 
Cash flows from financing activities:
   
     
 
Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs
 
 
—
 
 
 
83
 
                 
Net cash provided by financing activities
   
—  
      
83
 
                 
Net increase (decrease) in cash and cash equivalents
   
19,954
     
(9,886
 )
Cash and cash equivalents at beginning of period
   
46,697
     
57,379
 
                 
Cash and cash equivalents at end of period
  $
66,651
    $
47,493
 
                 
Supplemental disclosure of cash flow information:
   
     
 
Obtaining a
right-of-use
asset in exchange for a lease liability
   $
—  
     $
900
  
 
 
 
See accompanying notes to condensed consolidated financial statements.
5
MADRIGAL PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Organization, Business, and Basis of Presentation
Organization and Business
Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound,
MGL-3196
(resmetirom), is being advanced for
non-alcoholic
steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and
non-alcoholic
fatty liver disease (“NAFLD”). The Company initiated two Phase 3 studies of resmetirom in NASH in 2019. The Company previously completed Phase 2 studies of resmetirom in NASH in May of 2018 and Heterozygous Familial Hypercholesterolemia in February of 2018.
Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and operations commenced in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements.
Basis of Presentation
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ending December 31, 2020 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2019.
2. Summary of Significant Accounting Policies
Principle of Consolidation
The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.
The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.
6
Marketable Securities
Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.
 
The Company adjusts the cost of
available-for-sale
debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on
available-for-sale
securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three months ended March 31, 2020 and 2019, the Company determined it did not have any securities that were other-than-temporarily impaired.
Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three months ended March 31, 2020 and 2019, the Company did not have any realized gains or losses on marketable securities.
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.
Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.
As of March 31, 2020, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three months ended March 31, 2020 and 2019, the Company did not have any transfers of financial assets between Levels 1 and 2. As of March 31, 2020 and December 31, 2019, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted Phase
1-3
clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its preclinical studies and clinical trials, completion of milestones events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. The Company’s historical estimates for research and development costs have not been materially different from the actual costs.
7
Patents
Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.
Stock-Based Compensation
The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is
re-evaluated
at least annually and the forfeiture rate is adjusted as necessary.
Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets.
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.
Basic and Diluted Loss Per Common Share
Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three months ended March 31, 2020 and 2019, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive.
The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
Three Months Ended 
  
 
 
March 31,
 
  
2020
 
  
2019
 
Common stock options
   
1,728,112
     
1,367,077
 
Unvested restricted common stock
   
—  
      
52,063
 
Preferred stock
   
1,969,797
     
1,969,797
 
Recent Accounting Pronouncements
In June 2016, the FASB issued ASU
2016-13,
“Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires all or a portion of the amortized cost basis of a financial asset to be written off when it is deemed uncollectible. For public business entities that do not quali
f
y as a smaller reporting company, ASU
2016-13
is effective for annual and interim reporting periods beginning after December 15, 2019. The Company adopted ASU
2016-13
effective January 1, 2020. There was no significant impact from the adoption.
8
3. Liquidity and Uncertainties
The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations.
The Company has incurred losses since inception, including approximately $36.1 million for the three months ended March 31, 2020, resulting in an accumulated deficit of approximately $259.4 million as of March 31, 2020. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company’s common and Series A Convertible Preferred Stock.
The Company believes that its cash, cash equivalents and marketable securities at March 31, 2020 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.
4. Cash, Cash Equivalents and Marketable Securities
A summary of cash, cash equivalents and
available-for-sale
marketable securities held by the Company as of March 31, 2020 and December 31, 2019 is as follows (in thousands):
 
  
March 31, 2020
  
 
  
Cost
    
Unrealized
    
Unrealized
    
Fair
  
gains
    
losses
    
value
  
Cash and cash equivalents:
   
     
     
     
 
Cash (Level 1)
  $
1,668
     $
  —  
     $
—  
     $
1,668
  
Money market funds (Level 1)
   
63,532
      
—  
      
—  
      
63,532
  
Corporate debt securities due within 3 months of date of purchase (Level 2)
   
1,451
      
—  
      
—  
      
1,451
  
                                 
Total cash and cash equivalents
   
66,651
      
—  
      
—  
      
66,651
  
Marketable securities:
   
     
     
     
 
Corporate debt securities due within 1 year of date of purchase (Level 2)
   
320,478
      
680
      
(261
 )    
320,897
  
Corporate debt securities due within 1 to 2 years of date of purchase
(Level 2)
   
20,966
      
39
      
(43
 )    
20,962
  
                                 
Total cash, cash equivalents and marketable securities
  $
 
 
408,095
     $
719
     $
(304
 )   $
 
 
408,510
  
                                 
9
 
  
December 31, 2019
  
 
  
Cost
    
Unrealized
    
Unrealized
    
Fair
  
gains
    
losses
    
value
  
Cash and cash equivalents:
   
     
     
     
 
Cash (Level 1)
  $
1,772
     $
—  
     $
—  
     $
1,772
  
Money market funds (Level 1)
   
44,925
      
—  
      
—  
      
44,925
  
Corporate debt securities due within 3 months of date of purchase (Level 2)
   
—  
      
—  
      
—  
      
—  
  
                                 
Total cash and cash equivalents
   
46,697
      
—  
      
—  
      
46,697
  
Marketable securities:
   
     
     
     
 
Corporate debt securities due within 1 year of date of purchase (Level 2)
   
309,365
      
220
      
(40
 )    
309,545
  
Corporate debt securities due within 1 to 2 years of date of purchase
(Level 2)
   
82,767
      
39
      
(3
 )    
82,803
  
                                 
Total cash, cash equivalents and marketable securities
  $
 
 
438,829
     $
  259
     $
(43
 )   $
  439,045
  
                                 
5. Accrued Liabilities
Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands)
:
 
  
March 31,
 
  
December 31,
 
2020
 
  
2019
 
Accrued contract research costs
  $
  18,105
    $
  13,775
 
Compensation and benefits
   
1,124
     
2,779
 
Professional fees
   
816
     
1,177
 
Other
   
4,224
     
5,906
 
                 
   $
24,269
    $
23,637
 
                 
6. Stockholders’ Equity
Common Stock
Each common stockholder is entitled to one vote for each share of common stock held. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors.
The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.
Preferred Stock
The Series A Preferred Stock has a par value of $0.0001 per share and is convertible into shares of the common stock at a
one-to-one
ratio, subject
certain limitations
and
 
to adjustment
provisions
 
as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017 (the “Series A Certificate”). The terms of the Series A Preferred Stock are set forth in the Series A Certificate. Upon any liquidation, dissolution or
winding-up
of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an
as-if-converted-to
-Common-Stock
basis) in the net assets of the Company. Shares of the Series A Preferred
 
Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) generally equal to the dividend payable on each share of the Common Stock, on an as-converted basis.
1
0
7. Stock-based Compensation
T
he 2015 Stock Plan, as amended, is our primary plan through which equity based grants are awarded. We ceased making new awards under the 2006 Stock Plan upon adoption of the 2015 Stock Plan. The 2015 Stock Plan provides for the grant of incentive stock options,
non-statutory
stock options, restricted stock and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the Compensation Committee of the Board of Directors. The terms of stock options awarded under the 2015 Stock Plan, in general, are determined by the Compensation Committee, provided the exercise price per share generally shall not be set at less than the fair market value of a share of the common stock on the date of grant and the term shall not be greater than ten years from the date the option is granted. As of March 31, 2020, the Company had options outstanding to purchase 1,728,112 shares of its common stock, which includes options outstanding under its 2006 Stock Plan. As of March 31, 2020, 1,085,220 shares were available for future issuance.
The following table summarizes stock option activity during the three months ended March 31, 2020:
 
Shares
 
  
Weighted
average
exercise price
 
Outstanding at January 1, 2020
   
1,461,987
    $
  64.67
 
Options granted
   
266,125
     
90.75
 
                 
Outstanding at March 31, 2020
   
1,728,112
    $
68.69
 
                 
Exercisable at March 31, 2020
   
1,025,465
    $
45.81
 
The total cash received by the Company as a result of stock option exercises was $0 and $0.1 million, respectively, for the three months ended March 31, 2020 and 2019. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the three months ended March 31, 2020 and 2019 were $68.71 and $101.08, respectively.
Stock-Based Compensation Expense
Stock-based compensation expense during the three months ended March 31, 2020 and 2019 was as follows (in thousands):
 
Three Months Ended March 31,
 
  
2020
 
  
2019
 
Stock-based compensation expense by type of award:
   
     
 
Stock options
  $
  4,846
    $
  5,901
 
Restricted stock
   
—  
      
121
 
                 
Total stock-based compensation expense
  $
4,846
    $
6,022
 
                 
Effect of stock-based compensation expense by line item:
   
     
 
Research and development
  $
2,078
    $
1,877
 
General and administrative
   
2,768
     
4,145
 
                 
Total stock-based compensation expense included in net loss
  $
4,846
    $
6,022
 
                 
Unrecognized stock-based compensation expense on stock options as of March 31, 2020 was $44.2 million with a weighted average remaining period of 3.0 years.
8
. Commitments and Contingencies
 
 
The Company has a Research, Development and Commercialization Agreement with
Hoffmann-La
Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.
The agreement requires future milestone payments to Roche. Remaining milestones under the agreement total $8 million and are earned by achieving specified objectives related to future regulatory approval in the United States and Europe of a product developed from resmetirom. A single-digit royalty payment range is based on net sales of products developed from resmetirom, subject to certain reductions. Except as described above, the Company has not achieved any additional product development or regulatory milestones and had no Licensed Product sales for the three months ended March 31, 2020 and 2019.
The Company has entered into customary contractual arrangements and letters of intent in support of
its
 Phase 3 clinical trials.
1
1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form
 10-Q
contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on our beliefs and assumptions and on information currently available to us, but are subject to factors beyond our control. Forward-looking statements include but are not limited to statements or references concerning: our clinical trials, research and development activities, and the timing and results associated with the future development of our lead product candidate,
MGL-3196
(resmetirom); our primary and secondary study endpoints for resmetirom and the potential for achieving such endpoints and projections; optimal dosing levels for resmetirom; projections regarding potential future NASH resolution, safety, fibrosis treatment, cardiovascular effects, lipid treatment or biomarker effects with resmetirom; the predictive power of liver fat reduction on NASH resolution with fibrosis reduction; the achievement of enrollment objectives concerning patient number, safety database and/or timing for our studies; potential NASH or NAFLD patient risk profile benefits with resmetirom; our possible or assumed future results of operations and expenses, business strategies and plans, capital needs and financing plans, trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things. Forward-looking statements: reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events; include all statements that are not historical facts; and can be identified by terms such as “anticipates,” “be,” “believes,” “continue,” “could,” “demonstrates,” ”design,” “estimates,” “expects,” “forecasts,” “future,” “goal,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” ”predictive,” “projects,” “seeks,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Although management presently believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: our clinical development of resmetirom; enrollment uncertainties, generally and in relation to
COVID-19
mandatory lock-down measures and individual precautionary measures that may be implemented for an uncertain period of time; outcomes or trends from competitive studies; the risks of achieving potential benefits in studies that includes substantially more patients than our prior studies; the timing and outcomes of clinical studies of resmetirom; and the uncertainties inherent in clinical testing. Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s filings with the U.S. Securities and Exchange Commission for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. We specifically discuss these risks and uncertainties in greater detail in the section entitled “Risk Factors” in Part I, Item 1A of our Annual Report on Form
10-K
for the year ended December 31, 2019, as well as in our other filings with the SEC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The consolidated financial statements, included elsewhere in this Quarterly Report on Form
10-Q,
and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read together with our audited financial statements and accompanying notes for year ended December 31, 2019 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are included in our Annual Report on Form
 10-K.
In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As disclosed in this report, our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” included elsewhere in this report. Our operating results are not necessarily indicative of results that may occur for the full fiscal year or any other future period.
About Madrigal Pharmaceuticals, Inc.
Our Focus.
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Our lead product candidate,
MGL-3196
(resmetirom), is a proprietary, liver-directed, selective thyroid hormone receptor-ß, or
THR-
ß, agonist being developed as a once-daily oral pill that can potentially be used to treat a number of disease states with high unmet medical need, including
non-alcoholic
steatohepatitis, or NASH.
Our Patient Market Opportunity.
NASH is a serious inflammatory form of nonalcoholic fatty liver disease, or NAFLD. NAFLD has become the most common liver disease in the United States and other developed countries and is characterized by an accumulation of fat in the liver with no other apparent causes. NASH can progress to cirrhosis or liver failure, require liver transplantation and can also result in liver cancer. Progression of NASH to end stage liver disease will soon surpass all other causes of liver failure requiring liver transplantation. Importantly, beyond these critical conditions, NASH and NAFLD patients additionally suffer heightened
12
cardiovascular risk and, in fact, die more frequently from cardiovascular events than from liver disease. NASH and NAFLD have grown as a consequence of rising worldwide obesity-related disorders. In the United States alone, NAFLD is estimated to affect approximately 27% to 34% of the population, or an estimated 86 million to 108 million people, and approximately 10% to 20% of this population is projected to progress from NAFLD to NASH. Current estimates place NASH prevalence at approximately 9 million to 15 million people in the United States, or three percent to five percent of the population, with similar prevalence in Europe and Asia.
Our Completed Studies.
For NASH, we enrolled 125 patients in a Phase 2 clinical trial with resmetirom. We achieved the
12-week
primary endpoint for this Phase 2 clinical trial and reported the results in December 2017, and we reported positive topline
36-week
results at the conclusion of the Phase 2 clinical trial in May 2018. We have completed treatment in a
36-week,
open-label extension study in 31 participating NASH patients from our Phase 2 clinical trial, which includes 14 patients who received placebo in the main study. We also completed a 116 patient Phase 2 clinical trial and announced results in February 2018 for the use of resmetirom in patients with heterozygous familial hypercholesterolemia, or HeFH. In addition to the NASH and HeFH Phase 2 clinical trials, resmetirom has also been studied in eight completed Phase 1 trials in a total of 219 subjects. Resmetirom appeared to be safe and was well-tolerated in these trials, which included a single ascending dose trial, a multiple ascending dose trial, two drug interaction trials with statins, a multiple dose mass balance study, a single dose relative bioavailability study of tablet formulation versus capsule formulation, a multiple dose drug interaction study, and a multiple dose drug interaction with food effect study.
Our Ongoing and Planned Studies.
On March 28, 2019, the Company announced that it had initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. This double-blind, placebo-controlled study will be conducted at more than 150 sites in the United States and the rest of the world. Patients with liver biopsy confirmed NASH with stage 2 or 3 fibrosis will be randomized 1:1:1 to receive a single oral daily dose of placebo, resmetirom 80 mg or resmetirom 100 mg. A second liver biopsy at week 52 in the first 900 patients will be the basis of filing for subpart
H-accelerated
approval; the primary endpoint will be the percent of patients treated with either dose of resmetirom as compared with placebo who achieve NASH resolution on the week 52 liver biopsy, defined as the absence of hepatocyte ballooning (score=0), and minimal lobular inflammation (score
0-1),
associated with at least a
2-point
reduction in NAS (NAFLD Activity Score), and no worsening of fibrosis stage. Two key secondary endpoints are reduction in
LDL-cholesterol
and a
1-point
or more improvement in fibrosis stage on the week 52 biopsy with no worsening of NASH. Patients will continue in the study for a total of approximately 54 months, and will be evaluated for a composite clinical outcome including cirrhosis on liver biopsy, or a liver related event such a hepatic decompensation. The total anticipated enrollment is approximately 2,000 patients, and will include up to 15% high risk F1 fibrosis stage NASH patients whose efficacy responses will be evaluated as exploratory endpoints.
On December 10, 2019 the Company announced it had opened for enrollment
MAESTRO-NAFLD-1,
a
52-week,
double-blind, placebo controlled Phase 3 clinical study in 700 patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S. Key endpoints are safety, including safety biomarkers, LDL cholesterol, lipid biomarkers, and fibrosis biomarkers. Except for serial liver biopsies, the study protocol is similar to the MAESTRO-NASH study with resmetirom doses of 80 mg or 100 mg or placebo and includes key secondary lipid,
MRI-PDFF
and NASH biomarker endpoints. In addition,
MAESTRO-NAFLD-1
includes an open label arm in which up to 100 patients will be dosed with 100 mg resmetirom. The MAESTRO
-NAFLD-1
study will help support the adequacy of the safety database at the time of NDA submission for subpart H approval for treatment of NASH in patients with F2 or F3 fibrosis (MAESTRO-NASH, NASH resolution surrogate endpoint).
Recent Developments
Initiation of MAESTRO-NASH Phase 3 clinical trial
In March of 2019 we initiated a Phase 3 trial in NASH, described in detail above under “About Madrigal; Our Ongoing and Planned Studies.”
FDA grants Fast Track designation for resmetirom in NASH
In October 2019, FDA granted Fast Track designation to resmetirom for NASH.
Initiation of
MAESTRO-NAFLD-1
Phase 3 clinical trial
In December 2019 we initiated a Phase 3 trial in presumed NASH, described in detail above under “About Madrigal; Our Ongoing and Planned Studies.”
COVID pandemic
In April 2020 we announced that in response to guidance from regulatory agencies, measures for
COVID-19
at impacted sites have been put in place for its Phase 3 MAESTRO-NASH and
MAESTRO-NAFLD-1
studies, allowing both studies to continue without changes to the protocol. At a recently conducted Data Monitoring Committee (DMC) meeting it was recommended that Phase 3 studies proceed without modification.
13
Basis of Presentation
Research and Development Expenses
Research and development expenses primarily consist of costs associated with our research activities, including the preclinical and clinical development of our product candidates. We expense our research and development expenses as incurred. We contract with clinical research organizations to manage our clinical trials under agreed upon budgets for each study, with oversight by our clinical program managers. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Manufacturing expense includes costs associated with drug formulation development and clinical drug production. We do not track employee and facility related research and development costs by project, as we typically use our employee and infrastructure resources across multiple research and development programs. We believe that the allocation of such costs would be arbitrary and not be meaningful.
Our research and development expenses consist primarily of:
  • salaries and related expense, including stock-based compensation;
  • external expenses paid to clinical trial sites, contract research organizations, laboratories, database software and consultants that conduct clinical trials;
  • expenses related to development and the production of nonclinical and clinical trial supplies, including fees paid to contract manufacturers;
  • expenses related to preclinical studies;
  • expenses related to compliance with drug development regulatory requirements; and
  • other allocated expenses, which include direct and allocated expenses for depreciation of equipment and other supplies.
We expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we conduct our clinical studies programs, manufacturing and toxicology studies. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, additional drug manufacturing requirements, and later stage toxicology studies such as carcinogenicity studies. Our research and development expenses have increased year over year in each of 2019 and 2018 and we expect that our research and development expenses will increase substantially in the future. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success for each product candidate is affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Accordingly, we may never succeed in achieving marketing approval for any of our product candidates
Completion dates and costs for our clinical development programs as well as our research program can vary significantly for each current and future product candidate and are difficult to predict. As a result, we cannot estimate with any degree of certainty the costs we will incur in connection with the development of our product candidates at this point in time. We expect that we will make determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the scientific success of early research programs, results of ongoing and future clinical trials, our ability to enter into collaborative agreements with respect to programs or potential product candidates, as well as ongoing assessments as to each current or future product candidate’s commercial potential.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries, benefits and stock-based compensation expenses for employees, management costs, costs associated with obtaining and maintaining our patent portfolio, professional fees for accounting, auditing, consulting and legal services, liability insurance, and allocated overhead expenses.
We expect that our general and administrative expenses may increase in the future as we expand our operating activities, maintain and expand our patent portfolio and incur additional costs associated with being a public company and maintaining compliance with exchange listing and SEC requirements. We expect these potential increases will likely include management costs, legal fees, accounting fees, directors’ and officers’ liability insurance premiums and expenses associated with investor relations.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities as of the date of the financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued research and development expenses and stock-based compensation
14
expense. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. There have been no material changes in our critical accounting policies and significant judgments and estimates during the three months ended March 31, 2020, as compared to those disclosed in our Annual Report on Form
10-K
for the fiscal year ended December 31, 2019 filed with the SEC on February 26, 2020.
Results of Operations
Three Months Ended March 31, 2020 and 2019
The following table provides comparative unaudited results of operations for the three months ended March 31, 2020 and 2019 (in thousands):
                                 
 
Three Months Ended March 31,
   
Increase / (Decrease)
 
 
2020
 
  
2019
 
  
$
 
  
%
 
Research and Development Expenses
  $
33,400
    $
12,373
     
21,027
     
170
 %
General and Administrative Expenses
   
4,605
     
5,746
     
(1,141
 )    
(20
 %)
Interest (Income)
   
(1,870
 )    
(3,039
 )    
(1,169
 )    
(38
 %)
                                 
  $
36,135
    $
15,080
     
21,055
     
140
 %
Revenue
We had no revenue for the three months ended March 31, 2020 and 2019.
Research and Development Expenses
Our research and development expenses were $33.4 million for the three months ended March 31, 2020, compared to $12.4 million in the corresponding period in 2019. Research and development expenses increased by $21.0 million in the 2020 period due primarily to the additional activities related to the Phase 3 clinical trials initiated in 2019, an increase in head count, and an increase in
non-cash
stock compensation from stock option awards. We expect our research and development expenses to increase over time as we advance our clinical and preclinical development programs for resmetirom.
General and Administrative Expenses
Our general and administrative expenses were $4.6 million for the three months ended March 31, 2020, compared to $5.7 million in the corresponding period in 2019. General and administrative expenses decreased by $1.1 million in the 2020 period due primarily to a decrease in
non-cash
stock compensation from stock option awards, partially offset by increases in other general and administrative expenses. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for resmetirom, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.
Interest Income
Our net interest income was $1.9 million for the three months ended March 31, 2020, compared to $3.0 million in the corresponding period in 2019. The decrease in interest income was due primarily to a lower average principal balance in our investment account in 2020 and decreased interest rates.
Liquidity and Capital Resources
Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of convertible debt, shares of our common stock and shares of our preferred stock, and the proceeds from the Merger. Our most significant use of capital pertains to salaries and benefits for our employees, including clinical, scientific, operational, financial and management personnel, and external research and development expenses, such as clinical trials and preclinical activity related to our product candidates.
As of March 31, 2020, we had cash, cash equivalents and marketable securities totaling $408.5 million compared to $439.0 million as of December 31, 2019, with the decrease attributable to the funding of operations. Our cash and investment balances are held in a variety of interest bearing instruments, including obligations of U.S. government agencies, U.S. Treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.
15
We anticipate continuing to incur operating losses for the foreseeable future. While our rate of cash usage will likely increase in the future, in particular to support our product development and clinical trial efforts, we believe our available cash resources as of March 31, 2020 will be sufficient to fund our operations past one year from the issuance of the financial statements contained herein. Future capital requirements will be substantial and will depend on many factors. To meet future capital requirements, we will need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fundraising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our product candidates would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.
Cash Flows
The following table provides a summary of our net cash flow activity (in thousands):
                 
 
Three Months Ended March 31,
 
 
2020
 
  
2019
 
Net cash used in operating activities
  $
(30,506
 )   $
(6,478
 )
Net cash (used in) provided by investing activities
   
50,460
     
(3,491
 )
Net cash provided by financing activities
   
—  
      
83
 
                 
Net (decrease) increase in cash and cash equivalents
  $
19,954
    $
(9,886
 )
Net cash used in operating activities was $30.5 million for the three months ended March 31, 2020, compared to $6.5 million for the corresponding period in 2019. The use of cash in these periods resulted primarily from our losses from operations, as adjusted for
non-cash
charges for stock-based compensation, and changes in our working capital accounts.
Net cash provided by investing activities was $50.5 million for the three months ended March 31, 2020, compared to $3.5 million used in investing activities for the corresponding period in 2019. Net cash provided by investing activities for the three months ended March 31, 2020 consisted of $109.4 million from sales and maturities of marketable securities, partially offset by $58.6 million of purchases of marketable securities for our investment portfolio and $0.3 million of purchases of property and equipment. Net cash used by investing activities for the three months ended March 31, 2019 consisted of $173.8 million of purchases of marketable securities for our investment portfolio, partially offset by $170.4 million from sales and maturities of marketable securities.
Net cash provided by financing activities was $0 for the three months ended March 31, 2020, compared to $0.1 million for the corresponding period in 2019, which consisted of proceeds from exercise of stock options.
Contractual Obligations and Commitments
No significant changes to contractual obligations and commitments occurred during the three months ended March 31, 2020, as compared to those disclosed in our Annual Report on Form
10-K
for the fiscal year ended December 31, 2019 filed with the SEC on February 26, 2020.
Off-Balance
Sheet Arrangements
We do not have any off balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation
S-K.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Interest Rate Risk
Our exposure to market risk is confined to our cash, cash equivalents and marketable securities. We regularly review our investments and monitor the financial markets. We invest in high-quality financial instruments, primarily money market funds, U.S. government and agency securities, government-sponsored bond obligations and certain other corporate debt securities, with the effective duration of the portfolio less than twelve months and no security with an effective duration in excess of twenty-four months, which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term duration of our investment portfolio and the current risk profile of our investments, we believe that an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. We do not believe that we have any material exposure to interest rate risk or changes in credit ratings arising from our investments.
16
Effects of Inflation
Inflation generally affects us with increased cost of labor and clinical trial costs. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.
Item 4. Controls and Procedures.
Definition and Limitations of Disclosure Controls
Our disclosure controls and procedures (as defined in Rules
 13a-15(e)
 and
15d-15(e)
 under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.
We carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
Limitations on the Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rule
 13a-15(f)
 under the Exchange Act) during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.
Item 1A. Risk Factors.
Our business is subject to substantial risks and uncertainties. You should carefully consider the risk factors set forth below as well as the other information contained in this Quarterly Report on Form
10-Q
and in our other public filings in evaluating our business, including risk factors in our 2019 Annual Report on Form
10-K
for the year ended December 31, 2019, which was filed with the SEC on February 26, 2020 (collectively, our “Risk Factors”). Any of our Risk Factors either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects and the value of our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Form
10-Q.
See “Special Note Regarding Forward-Looking Statements” in this Form
10-Q.
There have been no material changes to the Risk Factors as previously disclosed in the Company’s 2019 Annual Report on Form
10-K,
except as follows:
The continuation or worsening of the
COVID-19
pandemic, which spread worldwide in the first quarter of 2020, may affect our ability to complete our ongoing clinical trials, disrupt regulatory activities and delay or disrupt commercialization of resmetirom, and may have other adverse effects on our stock price and business operations.
The
COVID-19
pandemic is causing many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security, and other measures. This outbreak and the resulting governmental measures have had a significant impact, both direct and indirect, on businesses and commerce, as supply chains have been disrupted; facilities and production have been suspended; unemployment has increased; and demand for certain goods and services, such as medical services and supplies, has spiked. The future progression of the pandemic and its effects on our business and operations are uncertain.
17
We and our contract research organizations (“CROs”) and contract manufacturing organizations (“CMO”) may face disruptions that may affect our ability to conduct and timely complete ongoing clinical trials including disruptions in procuring items that are essential for our development activities, such as materials and intermediates used in the manufacturing of resmetirom. We and our CROs and CMOs, as well as clinical trial sites, may face disruptions related to our ongoing clinical trials arising from staffing disruptions and limitations on our activities and the activities of our CROs and CMOs, and delays in the ability to obtain necessary institutional review board or other necessary site approvals or delays in site initiations or site monitoring visits, as well as other delays at clinical trial sites. We may also face limitations on enrollment and patients withdrawing from our clinical trials or not complying with the protocol procedures, which could delay completion of our clinical trials or adversely affect the data generated by our clinical trials. The response to the
COVID-19
pandemic also could redirect resources with respect to regulatory and intellectual property matters in a way that could adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures that are intended to limit
in-person
interactions. The pandemic has significantly impacted economies worldwide, which could result in adverse effects on our business and operations. Moreover, the pandemic has also caused significant disruptions in the financial markets, and may continue to cause such disruptions, which has led to increased trading volatility and significant stock price declines within the first quarter of 2020 and may adversely impact the future volatility and value of our stock and future trading in our stock.
In accordance with governmental pronouncements, we have instituted policies to facilitate working remotely. The continuation of personnel working from home (not only at Madrigal, but also at CROs, CMOs, clinical sites and governmental and supervisory bodies) may negatively impact our productivity, or disrupt, delay, or otherwise adversely impact our business. This could adversely impact our business operations or delay necessary interactions with regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors, including our CROs and CMOs. We cannot be certain what the overall impact of the
COVID-19
pandemic will be on our business. However, it has the potential to adversely affect our business, financial condition, results of operations, and prospects.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
We may not be able to continue clinical trials for resmetirom as planned if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In particular, because resmetirom is focused on specific patient populations, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. If the
COVID-19
pandemic continues, patient recruitment and enrollment in our clinical trials may be adversely affected, delayed or interrupted. Patients may choose to withdraw from our studies or we may choose to or be required to pause enrollment and or patient dosing in our ongoing clinical trials in order to preserve health resources and protect trial participants. It is unknown whether or how long pauses or disruptions could occur or continue.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
The exhibits filed or furnished as part of this Quarterly Report on Form
 10-Q
are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
18
EXHIBIT INDEX
                                                 
Exhibit
 
  
 
Incorporated by Reference
   
Filed
 
Number
 
  
Exhibit Description
 
Form
 
  
File No.
 
  
Exhibit
 
  
Filing Date
 
  
Herewith
 
                                                 
 
  31.1
       
     
     
     
     
X
 
                                                 
 
  31.2
       
     
     
     
     
X
 
                                                 
 
  32.1**
       
     
     
     
     
X
 
                                                 
 
101.INS
   
Inline XBRL Instance Document.
   
     
     
     
     
X
 
                                                 
 
101.SCH
   
Inline XBRL Taxonomy Extension Schema Document.
   
     
     
     
     
X
 
                                                 
 
101.CAL
   
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
   
     
     
     
     
X
 
                                                 
 
101.LAB
   
Inline XBRL Taxonomy Extension Label Linkbase Document.
   
     
     
     
     
X
 
                                                 
 
101.PRE
   
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
   
     
     
     
     
X
 
                                                 
 
101.DEF
   
Inline XBRL Taxonomy Extension Definition Linkbase Document.
   
     
     
     
     
X
 
                                                 
 
104
   
Inline XBRL for the cover page of this Annual Report on Form
10-K,
included in the Exhibit 101 Inline XBRL Document Set.
    
     
     
     
     
 
* Certain portions of this exhibit have been redacted in accordance with Item 601(b)(10) of Regulation
S-K.
** The certifications attached as Exhibit 32.1 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.
19
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
             
     
MADRIGAL PHARMACEUTICALS, INC.
             
Date: May 7, 2020
     
By:
 
/s/ Paul A. Friedman, M.D.
     
 
Paul A. Friedman, M.D.
     
 
Chief Executive Officer
(Principal Executive Officer)
             
Date: May 7, 2020
     
By:
 
/s/ Marc R. Schneebaum
     
 
Marc R. Schneebaum
     
 
Chief Financial Officer
(Principal Financial and Accounting Officer)
20
 EX-31.1 2 d848605dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul A. Friedman, M.D., certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Paul A. Friedman, M.D.
Paul A. Friedman, M.D.
Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)
Date: May 7, 2020
 EX-31.2 3 d848605dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc R. Schneebaum, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Marc R. Schneebaum
Marc R. Schneebaum
Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: May 7, 2020
 EX-32.1 4 d848605dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350)), each of the undersigned officers of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 7, 2020       /s/ Paul A. Friedman, M.D.
      Paul A. Friedman, M.D.
      Chief Executive Officer and Chairman of the Board
      (Principal Executive Officer)
Dated: May 7, 2020       /s/ Marc R. Schneebaum
      Marc R. Schneebaum
      Senior Vice President and Chief Financial Officer
      (Principal Financial and Accounting Officer)

These certifications accompany the Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 5 mdgl-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Organization, Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Liquidity and Uncertainties link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Cash, Cash Equivalents and Marketable Securities link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Stock-based Compensation link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Liquidity and Uncertainties (Details) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Stockholders' Equity - Common Stock (Details) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Stockholders' Equity - Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Stock-based Compensation - Stock Option (Details) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Stock-based Compensation - Expense (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 1032 - Statement - Condensed Consolidated Statements of Cash Flows Alternate 1 link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 mdgl-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 mdgl-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 mdgl-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 mdgl-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net loss $ (36,135) $ (15,080)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 4,846 6,022
Depreciation and amortization expense 125 28
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 175 888
Accounts payable (63) 1,889
Accrued expense 632 (179)
Accrued interest, net of interest received on maturity of investments (86) (46)
Net cash used in operating activities (30,506) (6,478)
Cash flows from investing activities:    
Purchases of marketable securities (58,647) (173,837)
Sales and maturities of marketable securities 109,421 170,387
Purchases of property and equipment, net of disposals (314) (41)
Net cash provided by (used in) investing activities 50,460 (3,491)
Cash flows from financing activities:    
Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs 0 83
Net cash provided by financing activities 0 83
Net increase (decrease) in cash and cash equivalents 19,954 (9,886)
Cash and cash equivalents at beginning of period 46,697 57,379
Cash and cash equivalents at end of period 66,651 47,493
Supplemental disclosure of cash flow information:    
Obtaining a right-of-use asset in exchange for a lease liability $ 0 $ 900
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 1,969,797 1,969,797
Preferred stock, shares outstanding 1,969,797 1,969,797
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 15,429,154 15,429,154
Common stock, shares outstanding 15,429,154 15,429,154
XML 12 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation (Tables)
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Summary of stock option activity
The following table summarizes stock option activity during the three months ended March 31, 2020:
 
Shares
 
  
Weighted
average
exercise price
 
Outstanding at January 1, 2020
   
1,461,987
    $
  64.67
 
Options granted
   
266,125
     
90.75
 
                 
Outstanding at March 31, 2020
   
1,728,112
    $
68.69
 
                 
Exercisable at March 31, 2020
   
1,025,465
    $
45.81
 
Schedule of stock-based compensation expense
Stock-based compensation expense during the three months ended March 31, 2020 and 2019 was as follows (in thousands):
 
Three Months Ended March 31,
 
  
2020
 
  
2019
 
Stock-based compensation expense by type of award:
   
     
 
Stock options
  $
  4,846
    $
  5,901
 
Restricted stock
   
—  
      
121
 
                 
Total stock-based compensation expense
  $
4,846
    $
6,022
 
                 
Effect of stock-based compensation expense by line item:
   
     
 
Research and development
  $
2,078
    $
1,877
 
General and administrative
   
2,768
     
4,145
 
                 
Total stock-based compensation expense included in net loss
  $
4,846
    $
6,022
 
                 
XML 13 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Cash, Cash Equivalents and Marketable Securities    
Total cash, cash equivalents and marketable securities, Unrealized gains $ 719 $ 259
Total cash, cash equivalents and marketable securities, Unrealized losses (304) (43)
Carrying value    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 66,651 46,697
Total cash, cash equivalents and marketable securities, Cost 408,095 438,829
Fair value    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 66,651 46,697
Total cash, cash equivalents and marketable securities, Fair value $ 408,510 $ 439,045
Corporate debt securities due within 3 months of date of purchase    
Cash, Cash Equivalents and Marketable Securities    
Maturity period from date of purchase to classify an investment as marketable securities 3 months 3 months
Corporate debt securities due within 3 months of date of purchase | Carrying value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents $ 1,451  
Corporate debt securities due within 3 months of date of purchase | Fair value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents $ 1,451  
Corporate debt securities due within 1 year of date of purchase    
Cash, Cash Equivalents and Marketable Securities    
Maturity period from date of purchase to classify an investment as marketable securities 1 year 1 year
Corporate debt securities due within 1 year of date of purchase | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, unrealized gains $ 680 $ 220
Marketable securities, unrealized losses (261) (40)
Corporate debt securities due within 1 year of date of purchase | Carrying value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, cost 320,478 309,365
Corporate debt securities due within 1 year of date of purchase | Fair value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, fair value $ 320,897 $ 309,545
Corporate debt securities due within 1 to 2 years of date of purchase | Maximum [Member]    
Cash, Cash Equivalents and Marketable Securities    
Maturity period from date of purchase to classify an investment as marketable securities 2 years 2 years
Corporate debt securities due within 1 to 2 years of date of purchase | Minimum [Member]    
Cash, Cash Equivalents and Marketable Securities    
Maturity period from date of purchase to classify an investment as marketable securities 1 year 1 year
Corporate debt securities due within 1 to 2 years of date of purchase | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, unrealized gains $ 39 $ 39
Marketable securities, unrealized losses (43) (3)
Corporate debt securities due within 1 to 2 years of date of purchase | Carrying value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, cost 20,966 82,767
Corporate debt securities due within 1 to 2 years of date of purchase | Fair value | Level 2    
Cash, Cash Equivalents and Marketable Securities    
Marketable securities, fair value 20,962 82,803
Cash | Carrying value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 1,668 1,772
Cash | Fair value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 1,668 1,772
Money market funds | Carrying value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents 63,532 44,925
Money market funds | Fair value | Level 1    
Cash, Cash Equivalents and Marketable Securities    
Cash and cash equivalents $ 63,532 $ 44,925
XML 14 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation - Stock Option (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Maximum      
Stock-based compensation expense      
Expiration period 10 years    
Stock options      
Stock-based compensation expense      
Options outstanding to purchase of common stock 1,461,987   1,728,112
Shares available for future issuance     1,085,220
Shares      
Outstanding at the beginning of the year (in shares) 1,461,987    
Options granted (in shares) 266,125    
Outstanding at the end of the year (in shares) 1,728,112    
Exercisable at the end of the year (in shares)     1,025,465
Weighted average exercise price      
Outstanding at the beginning of the year (in dollars per share) $ 64.67    
Options granted (in dollars per share) 90.75    
Outstanding at the end of the year (in dollars per share) $ 68.69    
Exercisable at the end of the year (in dollars per share)     $ 45.81
Additional disclosures      
Proceeds resulting from exercise of stock options $ 0.0 $ 0.1  
Weighted-average grant date fair value of options (in dollars per share) $ 68.71 $ 101.08  
XML 16 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Commitments and Contingencies    
Licensed product sales $ 0 $ 0
Research, Development and Commercialization Agreement | Hoffmann-La Roche ("Roche")    
Commitments and Contingencies    
Remainder of future milestone payments $ 8,000,000  
XML 17 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Accrued Liabilities
 3 Months Ended
Mar. 31, 2020
Accrued Liabilities, Current [Abstract]  
Accrued Liabilities
5. Accrued Liabilities
Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands)
:
 
  
March 31,
 
  
December 31,
 
2020
 
  
2019
 
Accrued contract research costs
  $
  18,105
    $
  13,775
 
Compensation and benefits
   
1,124
     
2,779
 
Professional fees
   
816
     
1,177
 
Other
   
4,224
     
5,906
 
                 
   $
24,269
    $
23,637
 
                 
XML 18 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Principle of Consolidation
Principle of Consolidation
The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.
The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.
Marketable Securities
Marketable Securities
Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.
 
The Company adjusts the cost of
available-for-sale
debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on
available-for-sale
securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three months ended March 31, 2020 and 2019, the Company determined it did not have any securities that were other-than-temporarily impaired.
Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three months ended March 31, 2020 and 2019, the Company did not have any realized gains or losses on marketable securities.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.
Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.
As of March 31, 2020, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three months ended March 31, 2020 and 2019, the Company did not have any transfers of financial assets between Levels 1 and 2. As of March 31, 2020 and December 31, 2019, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.
Research and Development Costs
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted Phase
1-3
clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its preclinical studies and clinical trials, completion of milestones events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. The Company’s historical estimates for research and development costs have not been materially different from the actual costs.
Patents
Patents
Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.
Stock-Based Compensation
Stock-Based Compensation
The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is
re-evaluated
at least annually and the forfeiture rate is adjusted as necessary.
Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets.
Income Taxes
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.
Basic and Diluted Loss Per Common Share
Basic and Diluted Loss Per Common Share
Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three months ended March 31, 2020 and 2019, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive.
The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
Three Months Ended 
  
 
 
March 31,
 
  
2020
 
  
2019
 
Common stock options
   
1,728,112
     
1,367,077
 
Unvested restricted common stock
   
—  
      
52,063
 
Preferred stock
   
1,969,797
     
1,969,797
 
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In June 2016, the FASB issued ASU
2016-13,
“Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires all or a portion of the amortized cost basis of a financial asset to be written off when it is deemed uncollectible. For public business entities that do not quali
f
y as a smaller reporting company, ASU
2016-13
is effective for annual and interim reporting periods beginning after December 15, 2019. The Company adopted ASU
2016-13
effective January 1, 2020. There was no significant impact from the adoption.
XML 19 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation - Unrecognized Expense (Details) - Stock options
$ in Millions
 3 Months Ended
Mar. 31, 2020
USD ($)
Unrecognized stock-based compensation expense  
Unrecognized stock compensation expense $ 44.2
Weighted average remaining period (in years) 3 years
XML 20 d848605d10q_htm.xml IDEA: XBRL DOCUMENT 0001157601 2020-03-31 0001157601 2019-12-31 0001157601 2020-01-01 2020-03-31 0001157601 2019-01-01 2019-03-31 0001157601 2020-05-04 0001157601 2018-12-31 0001157601 2019-03-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember mdgl:CorporateDebtSecurities2Member 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember mdgl:CorporateDebtSecurities2Member 2020-03-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2020-03-31 0001157601 mdgl:HoffmanLaRocheMember mdgl:ResearchDevelopmentAndCommercializationAgreementMember 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities3Member 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member 2020-03-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001157601 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001157601 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001157601 srt:MaximumMember 2020-01-01 2020-03-31 0001157601 mdgl:CorporateDebtSecurities2Member 2020-01-01 2020-03-31 0001157601 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0001157601 srt:MinimumMember mdgl:CorporateDebtSecurities3Member 2020-01-01 2020-03-31 0001157601 srt:MaximumMember mdgl:CorporateDebtSecurities3Member 2020-01-01 2020-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001157601 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001157601 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001157601 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001157601 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001157601 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities3Member 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member 2019-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-06-30 0001157601 mdgl:CorporateDebtSecurities2Member 2019-01-01 2019-12-31 0001157601 us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-12-31 0001157601 srt:MinimumMember mdgl:CorporateDebtSecurities3Member 2019-01-01 2019-12-31 0001157601 srt:MaximumMember mdgl:CorporateDebtSecurities3Member 2019-01-01 2019-12-31 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-06-01 2017-06-30 0001157601 us-gaap:CommonStockMember 2019-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001157601 us-gaap:RetainedEarningsMember 2019-12-31 0001157601 us-gaap:EmployeeStockOptionMember 2019-12-31 0001157601 us-gaap:PreferredStockMember 2019-12-31 0001157601 us-gaap:CommonStockMember 2020-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001157601 us-gaap:RetainedEarningsMember 2020-03-31 0001157601 us-gaap:PreferredStockMember 2020-03-31 0001157601 us-gaap:CommonStockMember 2018-12-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001157601 us-gaap:RetainedEarningsMember 2018-12-31 0001157601 us-gaap:PreferredStockMember 2018-12-31 0001157601 us-gaap:CommonStockMember 2019-03-31 0001157601 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001157601 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001157601 us-gaap:RetainedEarningsMember 2019-03-31 0001157601 us-gaap:PreferredStockMember 2019-03-31 iso4217:USD pure shares iso4217:USD shares mdgl:Vote false 2020 Q1 0001157601 --12-31 10-Q true 2020-03-31 false 001-33277 MADRIGAL PHARMACEUTICALS, INC. DE 04-3508648 Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428 267 824-2827 Common Stock, $0.0001 Par Value Per Share MDGL NASDAQ Yes Yes Large Accelerated Filer false false false 15429154 66651000 46697000 341859000 392348000 976000 1152000 409486000 440197000 1373000 1184000 598000 675000 411457000 442056000 1115000 1178000 24269000 23637000 319000 315000 25703000 25130000 279000 361000 279000 361000 25982000 25491000 0.0001 0.0001 5000000 5000000 1969797 1969797 1969797 1969797 0.0001 0.0001 200000000 200000000 15429154 15429154 15429154 15429154 2000 2000 644413000 639567000 415000 216000 -259355000 -223220000 385475000 416565000 411457000 442056000 33400000 12373000 4605000 5746000 38005000 18119000 -38005000 -18119000 1870000 3039000 -36135000 -15080000 -2.34 -0.98 15429154 15364465 -36135000 -15080000 199000 497000 -35936000 -14583000 1969797 15429154 2000 639567000 216000 -223220000 416565000 4846000 4846000 199000 199000 -36135000 -36135000 1969797 15429154 2000 644413000 415000 -259355000 385475000 1969797 15409023 2000 616573000 -319000 -139272000 476984000 8041 83 83 6022000 6022000 497000 497000 -15080000 -15080000 1969797 15417064 2000 622678000 178000 -154352000 468506000 -36135000 -15080000 4846000 6022000 125000 28000 -175000 -888000 -63000 1889000 632000 -179000 -86000 -46000 -30506000 -6478000 58647000 173837000 109421000 170387000 314000 41000 50460000 -3491000 0 83000 0 83000 19954000 -9886000 46697000 57379000 66651000 47493000 0 900000 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization, Business, and Basis of Presentation </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organization and Business </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MGL-3196</div> (resmetirom), is being advanced for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-alcoholic</div> steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-alcoholic</div> fatty liver disease (“NAFLD”). The Company initiated two Phase 3 studies of resmetirom in NASH in 2019. The Company previously completed Phase 2 studies of resmetirom in NASH in May of 2018 and Heterozygous Familial Hypercholesterolemia in February of 2018.</div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and operations commenced in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ending December 31, 2020 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2019. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principle of Consolidation </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits. </div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk. </div></div> <div style="margin-bottom:0.0001pt; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities </div></div></div></div><div style="margin-top:6.0pt; margin-right:0in; margin-bottom:.0001pt; margin-left:0in; line-height:normal; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets. </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"> </div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company adjusts the cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three months ended March 31, 2020 and 2019, the Company determined it did not have any securities that were other-than-temporarily impaired.</div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three months ended March 31, 2020 and 2019, the Company did not have any realized gains or losses on marketable securities. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company’s financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels: </div></div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—quoted prices in active markets for identical assets and liabilities. </div></div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2020, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three months ended March 31, 2020 and 2019, the Company did not have any transfers of financial assets between Levels 1 and 2. As of March 31, 2020 and December 31, 2019, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted Phase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3</div> clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its preclinical studies and clinical trials, completion of milestones events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. The Company’s historical estimates for research and development costs have not been materially different from the actual costs.</div> <div style="margin-bottom:0.0001pt; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Patents </div></div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; line-height: 11.5pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.</div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> at least annually and the forfeiture rate is adjusted as necessary.</div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and Diluted Loss Per Common Share </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three months ended March 31, 2020 and 2019, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive: </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="6" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td></tr> <tr> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">March 31,</div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock options </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,728,112 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,367,077 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52,063 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,969,797 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,969,797 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires all or a portion of the amortized cost basis of a financial asset to be written off when it is deemed uncollectible. For public business entities that do not quali<div style="letter-spacing: 0px; top: 0px;;display:inline;">f</div>y as a smaller reporting company, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is effective for annual and interim reporting periods beginning after December 15, 2019. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> effective January 1, 2020. There was no significant impact from the adoption.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principle of Consolidation </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits. </div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk. </div></div> <div style="margin-bottom:0.0001pt; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities </div></div></div></div><div style="margin-top:6.0pt; margin-right:0in; margin-bottom:.0001pt; margin-left:0in; line-height:normal; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets. </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"> </div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company adjusts the cost of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three months ended March 31, 2020 and 2019, the Company determined it did not have any securities that were other-than-temporarily impaired.</div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three months ended March 31, 2020 and 2019, the Company did not have any realized gains or losses on marketable securities. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company’s financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels: </div></div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—quoted prices in active markets for identical assets and liabilities. </div></div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2020, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three months ended March 31, 2020 and 2019, the Company did not have any transfers of financial assets between Levels 1 and 2. As of March 31, 2020 and December 31, 2019, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted Phase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3</div> clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its preclinical studies and clinical trials, completion of milestones events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. The Company’s historical estimates for research and development costs have not been materially different from the actual costs.</div> <div style="margin-bottom:0.0001pt; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Patents </div></div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; line-height: 11.5pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.</div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> at least annually and the forfeiture rate is adjusted as necessary.</div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets. </div></div> 1 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and Diluted Loss Per Common Share </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three months ended March 31, 2020 and 2019, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive: </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="6" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td></tr> <tr> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">March 31,</div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock options </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,728,112 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,367,077 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52,063 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,969,797 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,969,797 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive: </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="6" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td></tr> <tr> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">March 31,</div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock options </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,728,112 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,367,077 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52,063 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,969,797 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 3%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,969,797 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> 1728112 1367077 52063 1969797 1969797 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires all or a portion of the amortized cost basis of a financial asset to be written off when it is deemed uncollectible. For public business entities that do not quali<div style="letter-spacing: 0px; top: 0px;;display:inline;">f</div>y as a smaller reporting company, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is effective for annual and interim reporting periods beginning after December 15, 2019. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> effective January 1, 2020. There was no significant impact from the adoption.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Liquidity and Uncertainties </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations. </div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred losses since inception, including approximately $36.1 million for the three months ended March 31, 2020, resulting in an accumulated deficit of approximately $259.4 million as of March 31, 2020. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company’s common and Series A Convertible Preferred Stock. </div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that its cash, cash equivalents and marketable securities at March 31, 2020 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved. </div></div> -36100000 -259400000 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Cash, Cash Equivalents and Marketable Securities </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">A summary of cash, cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> marketable securities held by the Company as of March 31, 2020 and December 31, 2019 is as follows (in thousands):</div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">March 31, 2020</div></td> <td> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td rowspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Cost</div></td> <td rowspan="2" style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Fair</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">gains</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">losses</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">value</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,668</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  —  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,668</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63,532</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63,532</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 3 months of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,451</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,451</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 65%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66,651</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66,651</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 year of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">320,478</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">680</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(261</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">320,897</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 to 2 years of date of purchase<br/>(Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,966</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,962</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 65%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and marketable securities </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>408,095</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">719</div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(304</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>408,510</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 65%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <table border="0" cellpadding="0" cellspacing="0" style="width: 92%; font-size: 10pt; margin-right: auto; margin-left: auto; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 64%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">December 31, 2019</div></td> <td> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td rowspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Cost</div></td> <td rowspan="2" style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Fair</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">gains</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">losses</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">value</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,772</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,772</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44,925</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44,925</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 3 months of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46,697</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46,697</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 year of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">309,365</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">220</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(40</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">309,545</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 to 2 years of date of purchase<br/>(Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,767</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,803</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and marketable securities </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>438,829</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  259</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  439,045</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">A summary of cash, cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> marketable securities held by the Company as of March 31, 2020 and December 31, 2019 is as follows (in thousands):</div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">March 31, 2020</div></td> <td> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td rowspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Cost</div></td> <td rowspan="2" style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Fair</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">gains</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">losses</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">value</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,668</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  —  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,668</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63,532</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63,532</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 3 months of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,451</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,451</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 65%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66,651</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66,651</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 year of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">320,478</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">680</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(261</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">320,897</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 to 2 years of date of purchase<br/>(Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,966</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,962</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 65%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 65%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and marketable securities </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>408,095</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">719</div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(304</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>408,510</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 65%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <table border="0" cellpadding="0" cellspacing="0" style="width: 92%; font-size: 10pt; margin-right: auto; margin-left: auto; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 64%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">December 31, 2019</div></td> <td> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td rowspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> </div></td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" rowspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Cost</div></td> <td rowspan="2" style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Unrealized</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Fair</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">gains</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">losses</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">value</div></td> <td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,772</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,772</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds (Level 1) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44,925</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44,925</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 3 months of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46,697</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46,697</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 year of date of purchase (Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">309,365</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">220</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(40</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">309,545</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities due within 1 to 2 years of date of purchase<br/>(Level 2) </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,767</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(3</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,803</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 64%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and marketable securities </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>438,829</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  259</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(43</div></div></td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  439,045</div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 64%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> 1668000 1668000 63532000 63532000 P3M 1451000 1451000 66651000 66651000 P1Y 320478000 680000 261000 320897000 P1Y P2Y 20966000 39000 43000 20962000 408095000 719000 304000 408510000 1772000 1772000 44925000 44925000 P3M 46697000 46697000 P1Y 309365000 220000 40000 309545000 P1Y P2Y 82767000 39000 3000 82803000 438829000 259000 43000 439045000 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Accrued Liabilities </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands)<div style="display:inline;">:</div> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td rowspan="2" style="vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued contract research costs </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  18,105 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  13,775 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,124 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,779 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">816 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,177 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,224 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,906 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24,269 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23,637 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands)<div style="display:inline;">:</div> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td rowspan="2" style="vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td rowspan="2" style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="page-break-inside:avoid;font-size:8pt;"> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued contract research costs </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  18,105 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  13,775 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,124 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,779 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional fees </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">816 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,177 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,224 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,906 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24,269 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23,637 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> 18105000 13775000 1124000 2779000 816000 1177000 4224000 5906000 24269000 23637000 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Stockholders’ Equity </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each common stockholder is entitled to one vote for each share of common stock held. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors. </div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The Series A Preferred Stock has a par value of $0.0001 per share and is convertible into shares of the common stock at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one </div> ratio, subject <div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">certain limitations </div><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>to adjustment <div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">provisions<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017 (the “Series A Certificate”). The terms of the Series A Preferred Stock are set forth in the Series A Certificate. Upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to</div>-Common-Stock</div> basis) in the net assets of the Company. Shares of the Series A Preferred<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) generally equal to the dividend payable on each share of the Common Stock, on an as-converted basis. </div></div> 1 0.0001 1 0 <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Stock-based Compensation </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">T</div>he 2015 Stock Plan, as amended, is our primary plan through which equity based grants are awarded. We ceased making new awards under the 2006 Stock Plan upon adoption of the 2015 Stock Plan. The 2015 Stock Plan provides for the grant of incentive stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options, restricted stock and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the Compensation Committee of the Board of Directors. The terms of stock options awarded under the 2015 Stock Plan, in general, are determined by the Compensation Committee, provided the exercise price per share generally shall not be set at less than the fair market value of a share of the common stock on the date of grant and the term shall not be greater than ten years from the date the option is granted. As of March 31, 2020, the Company had options outstanding to purchase 1,728,112 shares of its common stock, which includes options outstanding under its 2006 Stock Plan. As of March 31, 2020, 1,085,220 shares were available for future issuance.</div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes stock option activity during the three months ended March 31, 2020: </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 74%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted<br/>average<br/>exercise price </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2020 </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,461,987 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  64.67 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">266,125 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90.75 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 74%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at March 31, 2020 </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,728,112 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68.69 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 74%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at March 31, 2020 </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,025,465 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45.81 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total cash received by the Company as a result of stock option exercises was $0 and $0.1 million, respectively, for the three months ended March 31, 2020 and 2019. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the three months ended March 31, 2020 and 2019 were $68.71 and $101.08, respectively. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation Expense </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense during the three months ended March 31, 2020 and 2019 was as follows (in thousands): </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended March 31, </div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense by type of award: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  4,846 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  5,901 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,846 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,022 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of stock-based compensation expense by line item: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,078 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,877 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,768 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,145 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense included in net loss </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,846 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,022 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized stock-based compensation expense on stock options as of March 31, 2020 was $44.2 million with a weighted average remaining period of 3.0 years.</div></div> P10Y 1728112 1085220 <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes stock option activity during the three months ended March 31, 2020: </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 74%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted<br/>average<br/>exercise price </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 1, 2020 </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,461,987 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  64.67 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">266,125 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90.75 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 74%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at March 31, 2020 </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,728,112 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68.69 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 74%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 74%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at March 31, 2020 </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,025,465 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45.81 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> 1461987 64.67 266125 90.75 1728112 68.69 1025465 45.81 0 100000 68.71 101.08 <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense during the three months ended March 31, 2020 and 2019 was as follows (in thousands): </div></div> <table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/> <td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended March 31, </div></div></div></td> <td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td></tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td> <td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;"> </div></td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense by type of award: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  4,846 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">  5,901 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,846 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,022 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of stock-based compensation expense by line item: </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,078 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,877 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,768 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"> </td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,145 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 10pt; page-break-inside: avoid;"> <td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense included in net loss </div></div></td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,846 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,022 </div></div></td> <td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-size: 0pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;"> </td> <td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> 4846000 5901000 0 121000 4846000 6022000 2078000 1877000 2768000 4145000 4846000 6022000 44200000 P3Y <div style="text-align: left;font-family: Times New Roman;font-size: 10pt;margin-top: 18pt;margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>. Commitments and Contingencies </div></div></div> <div style="clear: both; max-height: 0px;"> </div> <div style="clear: both; max-height: 0px;"> </div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The Company has a Research, Development and Commercialization Agreement with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hoffmann-La</div> Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.</div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The agreement requires future milestone payments to Roche. Remaining milestones under the agreement total $8 million and are earned by achieving specified objectives related to future regulatory approval in the United States and Europe of a product developed from resmetirom. A single-digit royalty payment range is based on net sales of products developed from resmetirom, subject to certain reductions. Except as described above, the Company has not achieved any additional product development or regulatory milestones and had no Licensed Product sales for the three months ended March 31, 2020 and 2019. </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into customary contractual arrangements and letters of intent in support of <div style="letter-spacing: 0px; top: 0px;;display:inline;">its</div> Phase 3 clinical trials. </div></div> 8000000 0 0 XML 21 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity
 3 Months Ended
Mar. 31, 2020
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
6. Stockholders’ Equity
Common Stock
Each common stockholder is entitled to one vote for each share of common stock held. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors.
The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.
Preferred Stock
The Series A Preferred Stock has a par value of $0.0001 per share and is convertible into shares of the common stock at a
one-to-one
ratio, subject
certain limitations
and
 
to adjustment
provisions
 
as provided in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017 (the “Series A Certificate”). The terms of the Series A Preferred Stock are set forth in the Series A Certificate. Upon any liquidation, dissolution or
winding-up
of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an
as-if-converted-to
-Common-Stock
basis) in the net assets of the Company. Shares of the Series A Preferred
 
Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) generally equal to the dividend payable on each share of the Common Stock, on an as-converted basis.
XML 22 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive
The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
Three Months Ended 
  
 
 
March 31,
 
  
2020
 
  
2019
 
Common stock options
   
1,728,112
     
1,367,077
 
Unvested restricted common stock
   
—  
      
52,063
 
Preferred stock
   
1,969,797
     
1,969,797
 
JSON 23 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d848605d10q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 87, "dts": { "calculationLink": { "local": [ "mdgl-20200331_cal.xml" ] }, "definitionLink": { "local": [ "mdgl-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d848605d10q.htm" ] }, "labelLink": { "local": [ "mdgl-20200331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mdgl-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mdgl-20200331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 240, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 5 }, "keyCustom": 15, "keyStandard": 197, "memberCustom": 5, "memberStandard": 18, "nsprefix": "mdgl", "nsuri": "http://www.madrigalpharma.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.madrigalpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Liquidity and Uncertainties", "role": "http://www.madrigalpharma.com/role/LiquidityAndUncertainties", "shortName": "Liquidity and Uncertainties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Cash, Cash Equivalents and Marketable Securities", "role": "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities", "shortName": "Cash, Cash Equivalents and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "mdgl:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Accrued Liabilities", "role": "http://www.madrigalpharma.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "mdgl:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Stockholders' Equity", "role": "http://www.madrigalpharma.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Stock-based Compensation", "role": "http://www.madrigalpharma.com/role/StockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Commitments and Contingencies", "role": "http://www.madrigalpharma.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)", "role": "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables", "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Accrued Liabilities (Tables)", "role": "http://www.madrigalpharma.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Stock-based Compensation (Tables)", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "2", "first": true, "lang": null, "name": "mdgl:DeferredTaxAssetsPercentageOfValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails", "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "2", "first": true, "lang": null, "name": "mdgl:DeferredTaxAssetsPercentageOfValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details)", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails", "shortName": "Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Liquidity and Uncertainties (Details)", "role": "http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails", "shortName": "Liquidity and Uncertainties (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details)", "role": "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails", "shortName": "Cash, Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:AccruedContractResearchCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Accrued Liabilities (Details)", "role": "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "mdgl:AccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "mdgl:AccruedContractResearchCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "mdgl:CommonStockVotingRightsNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Vote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Stockholders' Equity - Common Stock (Details)", "role": "http://www.madrigalpharma.com/role/StockholdersEquityCommonStockDetails", "shortName": "Stockholders' Equity - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "mdgl:CommonStockVotingRightsNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Vote", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Stockholders' Equity - Preferred Stock (Details)", "role": "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails", "shortName": "Stockholders' Equity - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn06_30_2017_ConvertibleSeriesPreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020_MaximumMembersrtRangeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Stock-based Compensation - Stock Option (Details)", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "shortName": "Stock-based Compensation - Stock Option (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020_MaximumMembersrtRangeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "mdgl:ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Stock-based Compensation - Expense (Details)", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "mdgl:ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details)", "role": "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails", "shortName": "Stock-based Compensation - Unrecognized Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Organization, Business and Basis of Presentation", "role": "http://www.madrigalpharma.com/role/OrganizationBusinessAndBasisOfPresentation", "shortName": "Organization, Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d848605d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 26, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mdgl_AccruedCompensationAndBenefitsCurrent": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Compensation And Benefits, Current.", "label": "Accrued Compensation And Benefits Current", "verboseLabel": "Compensation and benefits" } } }, "localname": "AccruedCompensationAndBenefitsCurrent", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_AccruedContractResearchCostsCurrent": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Contract Research Costs, Current.", "label": "Accrued Contract Research Costs Current", "verboseLabel": "Accrued contract research costs" } } }, "localname": "AccruedContractResearchCostsCurrent", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_AccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued Liabilities Disclosure.", "label": "Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "mdgl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the gross unrealized gains for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.", "label": "Cash and Cash Equivalents and Available for Sale Securities, Gross Unrealized Gains", "terseLabel": "Total cash, cash equivalents and marketable securities, Unrealized gains" } } }, "localname": "CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the gross unrealized losses for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.", "label": "Cash and Cash Equivalents and Available for Sale Securities, Gross Unrealized Losses", "negatedLabel": "Total cash, cash equivalents and marketable securities, Unrealized losses" } } }, "localname": "CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CashCashEquivalentsAndShortTermInvestmentsAtCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings, and cash and cash equivalents.", "label": "Cash, Cash Equivalents, and Short-term Investments, At Cost", "terseLabel": "Total cash, cash equivalents and marketable securities, Cost" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsAtCost", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_CommonStockVotingRightsNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of votes per share that common stockholders are entitled to receive.", "label": "Common Stock Voting Rights Number", "terseLabel": "Number of votes per share that common stockholders are entitled to receive" } } }, "localname": "CommonStockVotingRightsNumber", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityCommonStockDetails" ], "xbrltype": "integerItemType" }, "mdgl_ConvertibleSeriesPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Series Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "ConvertibleSeriesPreferredStockMember", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "domainItemType" }, "mdgl_CorporateDebtSecurities2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities due within 3 months issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities2 [Member]", "terseLabel": "Corporate debt securities due within 3 months of date of purchase" } } }, "localname": "CorporateDebtSecurities2Member", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "mdgl_CorporateDebtSecurities3Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate Debt Securities 3", "label": "Corporate Debt Securities 3 [Member]", "terseLabel": "Corporate debt securities due within 1 to 2 years of date of purchase" } } }, "localname": "CorporateDebtSecurities3Member", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "mdgl_DeferredTaxAssetsPercentageOfValuationAllowance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of valuation allowance on the deferred tax assets.", "label": "Deferred Tax Assets, Percentage Of Valuation Allowance", "terseLabel": "Valuation allowance on deferred tax assets (as a percent)" } } }, "localname": "DeferredTaxAssetsPercentageOfValuationAllowance", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "mdgl_HoffmanLaRocheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Hoffman-La Roche.", "label": "Hoffman La Roche [Member]", "terseLabel": "Hoffmann-La Roche (\"Roche\")" } } }, "localname": "HoffmanLaRocheMember", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "mdgl_IncreaseDecreaseInAccruedInterestNetOfInterestReceived": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of accrued interest expense incurred but not yet paid, net of interest received on maturity of investments.", "label": "Increase (Decrease) In Accrued Interest, Net Of Interest Received", "terseLabel": "Accrued interest, net of interest received on maturity of investments" } } }, "localname": "IncreaseDecreaseInAccruedInterestNetOfInterestReceived", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdgl_LiquidityAndUncertaintiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liquidity And Uncertainties Disclosure Abstract", "label": "Liquidity and Uncertainties" } } }, "localname": "LiquidityAndUncertaintiesDisclosureAbstract", "nsuri": "http://www.madrigalpharma.com/20200331", "xbrltype": "stringItemType" }, "mdgl_MaturityPeriodFromDateOfPurchaseToClassifyInvestmentAsMarketableSecurities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the maturity period from date of purchase to classify an investment as marketable securities.", "label": "Maturity Period from Date of Purchase to Classify Investment as Marketable Securities", "terseLabel": "Maturity period from date of purchase to classify an investment as marketable securities" } } }, "localname": "MaturityPeriodFromDateOfPurchaseToClassifyInvestmentAsMarketableSecurities", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "durationItemType" }, "mdgl_PatentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for patents.", "label": "Patents [Policy Text Block]", "terseLabel": "Patents" } } }, "localname": "PatentsPolicyTextBlock", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mdgl_PreferredStockNumberOfVotingRights": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of voting rights of preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Number Of Voting Rights", "terseLabel": "Preferred shares number voting rights" } } }, "localname": "PreferredStockNumberOfVotingRights", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "integerItemType" }, "mdgl_ProceedsFromTheSaleOfRelatedPartyStockAndExerciseOfCommonStockOptionsNetOfTransactionCosts": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsAlternate1": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs.", "label": "Proceeds From The Sale Of Related Party Stock And Exercise Of Common Stock Options Net Of Transaction Costs", "terseLabel": "Proceeds from the sale of related party stock and exercise of common stock options, net of transaction costs" } } }, "localname": "ProceedsFromTheSaleOfRelatedPartyStockAndExerciseOfCommonStockOptionsNetOfTransactionCosts", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdgl_RemainingMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of future milestone payments remaining to be paid under the agreement.", "label": "Remaining Milestone Payments", "verboseLabel": "Remainder of future milestone payments" } } }, "localname": "RemainingMilestonePayments", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "mdgl_ResearchDevelopmentAndCommercializationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Research, Development and Commercialization Agreement with Hoffmann-La Roche (\"Roche\") which grants a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.", "label": "Research Development And Commercialization Agreement [Member]", "terseLabel": "Research, Development and Commercialization Agreement" } } }, "localname": "ResearchDevelopmentAndCommercializationAgreementMember", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "mdgl_ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the income statement for the period. This may include the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. It includes the reporting line for the costs expensed.", "label": "Schedule of Share Based Compensation Expense Allocation of Compensation Costs and Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationExpenseAllocationOfCompensationCostsAndRecognizedPeriodCostsTableTextBlock", "nsuri": "http://www.madrigalpharma.com/20200331", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r66" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "verboseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails", "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r5", "r6", "r29" ], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r36", "r37", "r38" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive gain (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r35", "r38", "r39", "r155" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Compensation expense related to stock options for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r121", "r135", "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r83", "r182", "r187" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r33" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Marketable securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Marketable securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r89", "r99" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "verboseLabel": "Marketable securities, cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r86", "r90", "r99" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Marketable securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r88", "r99" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r122", "r137" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r168", "r169" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r26", "r59" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r60", "r65" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r11", "r93" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash, Cash Equivalents and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "verboseLabel": "Total cash, cash equivalents and marketable securities, Fair value" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r54", "r59", "r64" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r54", "r170" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r106", "r107" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r108" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.0001 per share authorized: 200,000,000 at March 31, 2020 and December 31, 2019; 15,429,154 shares issued and outstanding at March 31, 2020 and December 31, 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r65", "r151", "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principle of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r61", "r62", "r63" ], "lang": { "en-US": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Preferred stock conversion ratio" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r117", "r119", "r192" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities due within 1 year of date of purchase" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r31", "r67", "r109", "r110", "r111", "r112", "r171", "r172", "r173", "r186" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r57", "r82" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r65", "r71", "r72", "r73" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Loss Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r136" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails", "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r117", "r118", "r119", "r162", "r178" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r161", "r163" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r117", "r118", "r119", "r162", "r179" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r117", "r118", "r119", "r162", "r180" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r65", "r164", "r166" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r94", "r95", "r96", "r97", "r98", "r100", "r101", "r102", "r103" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r105" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r45", "r65", "r142", "r143", "r144", "r145", "r146", "r147", "r194" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r56" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expense" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r56" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r183", "r189" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r14", "r15" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 }, "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsAlternate1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r55", "r58" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r40", "r42", "r46", "r58", "r72", "r184", "r191" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r175" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r175" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r174" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/OrganizationBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r68", "r69", "r81", "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r29" ], "calculation": { "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r149", "r150", "r154" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain on available-for-sale securities", "verboseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r87" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment, net of disposals" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2020 and December 31, 2019; 1,969,797 shares issued and outstanding at March 31, 2020 and December 31, 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r24", "r25" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r49", "r50", "r87" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Sales and maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r52", "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds resulting from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r40", "r42", "r53", "r83", "r84", "r149", "r152", "r153", "r156", "r157" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r104", "r190" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r141" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r65", "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted common stock", "verboseLabel": "Unvested restricted common stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r113", "r188" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r115", "r116" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Licensed product sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r176", "r177" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Obtaining a right-of-use asset in exchange for a lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of cash, cash equivalents and available-for-sale marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Cash, Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r122", "r137" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r126", "r131", "r133" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r56" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Unrecognized stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of the year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of the year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r128", "r137" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the year (in shares)", "periodStartLabel": "Outstanding at the beginning of the year (in shares)", "terseLabel": "Options outstanding to purchase of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the year (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r120", "r124" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails", "http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r65", "r122", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r108" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r108" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r108", "r113", "r130" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r85" ], "calculation": { "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Liquidity and Uncertainties" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/LiquidityAndUncertainties" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Major Types of Debt and Equity Securities [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r74", "r75", "r76", "r77", "r78", "r79", "r80" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r195": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r196": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r197": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r198": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r199": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" } }, "version": "2.1" } XML 24 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Preferred Stock
Common stock
Additional paid-in Capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Balance at Dec. 31, 2018 $ 476,984   $ 2 $ 616,573 $ (319) $ (139,272)
Balance (in shares) at Dec. 31, 2018   1,969,797 15,409,023      
Increase (Decrease) in Stockholders' Equity            
Exercise of common stock options (in shares) 83   8,041 83    
Compensation expense related to stock options for services $ 6,022     $ 6,022    
Unrealized gain (loss) on marketable securities 497       497  
Net loss (15,080)         (15,080)
Balance at Mar. 31, 2019 468,506   $ 2 622,678 178 (154,352)
Balance (in shares) at Mar. 31, 2019   1,969,797 15,417,064      
Balance at Dec. 31, 2019 $ 416,565   $ 2 639,567 216 (223,220)
Balance (in shares) at Dec. 31, 2019 15,429,154 1,969,797 15,429,154      
Increase (Decrease) in Stockholders' Equity            
Compensation expense related to stock options for services $ 4,846     4,846    
Unrealized gain (loss) on marketable securities 199       199  
Net loss (36,135)         (36,135)
Balance at Mar. 31, 2020 $ 385,475   $ 2 $ 644,413 $ 415 $ (259,355)
Balance (in shares) at Mar. 31, 2020 15,429,154 1,969,797 15,429,154      
XML 25 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 66,651 $ 46,697
Marketable securities 341,859 392,348
Prepaid expenses and other current assets 976 1,152
Total current assets 409,486 440,197
Property and equipment, net 1,373 1,184
Right-of-use asset 598 675
Total assets 411,457 442,056
Current liabilities:    
Accounts payable 1,115 1,178
Accrued expenses 24,269 23,637
Lease liability 319 315
Total current liabilities 25,703 25,130
Long-term liabilities:    
Lease liability 279 361
Total long term liabilities 279 361
Total liabilities 25,982 25,491
Stockholders' equity:    
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2020 and December 31, 2019; 1,969,797 shares issued and outstanding at March 31, 2020 and December 31, 2019
Common stock, par value $0.0001 per share authorized: 200,000,000 at March 31, 2020 and December 31, 2019; 15,429,154 shares issued and outstanding at March 31, 2020 and December 31, 2019 2 2
Additional paid-in-capital 644,413 639,567
Accumulated other comprehensive gain (loss) 415 216
Accumulated deficit (259,355) (223,220)
Total stockholders' equity 385,475 416,565
Total liabilities and stockholders' equity $ 411,457 $ 442,056
XML 26 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation - Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Stock-based compensation expense    
Stock-based compensation expense $ 4,846 $ 6,022
Research and development    
Stock-based compensation expense    
Stock-based compensation expense 2,078 1,877
General and administrative    
Stock-based compensation expense    
Stock-based compensation expense 2,768 4,145
Stock options    
Stock-based compensation expense    
Stock-based compensation expense 4,846 5,901
Unvested restricted common stock    
Stock-based compensation expense    
Stock-based compensation expense $ 0 $ 121
XML 27 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Income Taxes (Details)
 3 Months Ended
Mar. 31, 2020
Income Taxes  
Valuation allowance on deferred tax assets (as a percent) 100.00%
XML 28 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Accrued Liabilities, Current [Abstract]    
Accrued contract research costs $ 18,105 $ 13,775
Compensation and benefits 1,124 2,779
Professional fees 816 1,177
Other 4,224 5,906
Total $ 24,269 $ 23,637
XML 29 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 30 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Cash, Cash Equivalents and Marketable Securities
 3 Months Ended
Mar. 31, 2020
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Marketable Securities
4. Cash, Cash Equivalents and Marketable Securities
A summary of cash, cash equivalents and
available-for-sale
marketable securities held by the Company as of March 31, 2020 and December 31, 2019 is as follows (in thousands):
 
  
March 31, 2020
  
 
  
Cost
    
Unrealized
    
Unrealized
    
Fair
  
gains
    
losses
    
value
  
Cash and cash equivalents:
   
     
     
     
 
Cash (Level 1)
  $
1,668
     $
  —  
     $
—  
     $
1,668
  
Money market funds (Level 1)
   
63,532
      
—  
      
—  
      
63,532
  
Corporate debt securities due within 3 months of date of purchase (Level 2)
   
1,451
      
—  
      
—  
      
1,451
  
                                 
Total cash and cash equivalents
   
66,651
      
—  
      
—  
      
66,651
  
Marketable securities:
   
     
     
     
 
Corporate debt securities due within 1 year of date of purchase (Level 2)
   
320,478
      
680
      
(261
 )    
320,897
  
Corporate debt securities due within 1 to 2 years of date of purchase
(Level 2)
   
20,966
      
39
      
(43
 )    
20,962
  
                                 
Total cash, cash equivalents and marketable securities
  $
 
 
408,095
     $
719
     $
(304
 )   $
 
 
408,510
  
                                 
 
  
December 31, 2019
  
 
  
Cost
    
Unrealized
    
Unrealized
    
Fair
  
gains
    
losses
    
value
  
Cash and cash equivalents:
   
     
     
     
 
Cash (Level 1)
  $
1,772
     $
—  
     $
—  
     $
1,772
  
Money market funds (Level 1)
   
44,925
      
—  
      
—  
      
44,925
  
Corporate debt securities due within 3 months of date of purchase (Level 2)
   
—  
      
—  
      
—  
      
—  
  
                                 
Total cash and cash equivalents
   
46,697
      
—  
      
—  
      
46,697
  
Marketable securities:
   
     
     
     
 
Corporate debt securities due within 1 year of date of purchase (Level 2)
   
309,365
      
220
      
(40
 )    
309,545
  
Corporate debt securities due within 1 to 2 years of date of purchase
(Level 2)
   
82,767
      
39
      
(3
 )    
82,803
  
                                 
Total cash, cash equivalents and marketable securities
  $
 
 
438,829
     $
  259
     $
(43
 )   $
  439,045
  
                                 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
8
. Commitments and Contingencies
 
 
The Company has a Research, Development and Commercialization Agreement with
Hoffmann-La
Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.
The agreement requires future milestone payments to Roche. Remaining milestones under the agreement total $8 million and are earned by achieving specified objectives related to future regulatory approval in the United States and Europe of a product developed from resmetirom. A single-digit royalty payment range is based on net sales of products developed from resmetirom, subject to certain reductions. Except as described above, the Company has not achieved any additional product development or regulatory milestones and had no Licensed Product sales for the three months ended March 31, 2020 and 2019.
The Company has entered into customary contractual arrangements and letters of intent in support of
its
 Phase 3 clinical trials.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2020
Accrued Liabilities, Current [Abstract]  
Schedule of Accrued Liabilities
Accrued liabilities as of March 31, 2020 and December 31, 2019 consisted of the following (in thousands)
:
 
  
March 31,
 
  
December 31,
 
2020
 
  
2019
 
Accrued contract research costs
  $
  18,105
    $
  13,775
 
Compensation and benefits
   
1,124
     
2,779
 
Professional fees
   
816
     
1,177
 
Other
   
4,224
     
5,906
 
                 
   $
24,269
    $
23,637
 
                 
XML 33 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 34 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Organization, Business and Basis of Presentation
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Business and Basis of Presentation
1. Organization, Business, and Basis of Presentation
Organization and Business
Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound,
MGL-3196
(resmetirom), is being advanced for
non-alcoholic
steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and
non-alcoholic
fatty liver disease (“NAFLD”). The Company initiated two Phase 3 studies of resmetirom in NASH in 2019. The Company previously completed Phase 2 studies of resmetirom in NASH in May of 2018 and Heterozygous Familial Hypercholesterolemia in February of 2018.
Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and operations commenced in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements.
Basis of Presentation
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ending December 31, 2020 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2019.
XML 35 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development $ 33,400 $ 12,373
General and administrative 4,605 5,746
Total operating expenses 38,005 18,119
Loss from operations (38,005) (18,119)
Interest income 1,870 3,039
Net loss $ (36,135) $ (15,080)
Net loss per common share:    
Basic and diluted net loss per common share (in dollars per share) $ (2.34) $ (0.98)
Basic and diluted weighted average number of common shares outstanding 15,429,154 15,364,465
EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Liquidity and Uncertainties (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Liquidity and Uncertainties      
Net loss $ 36,135 $ 15,080  
Accumulated deficit $ 259,355   $ 223,220
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity - Preferred Stock (Details)
 1 Months Ended
Jun. 30, 2017
Vote
$ / shares
shares
Mar. 31, 2020
$ / shares
Dec. 31, 2019
$ / shares
Stockholders' Equity (Deficit)      
Preferred stock, par value (in dollars per share)   $ 0.0001 $ 0.0001
Series A Convertible Preferred Stock      
Stockholders' Equity (Deficit)      
Preferred stock, par value (in dollars per share) $ 0.0001    
Preferred stock conversion ratio | shares 1    
Preferred shares number voting rights | Vote 0    
ZIP 39 0001193125-20-135312-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-135312-xbrl.zip M4$L#!!0 ( &TPIU!/\3J<K(F27[I;*U;6ALEW=WO5M+-6<<]XO%1 )6>RB M2 U!VM;\^C<3("E2HF3=14HYT>.R)1($@3ON<-/W_Z M]/KZ>C9@AFL^,VO89^Z G>G.X%.Y6"X6*Y7227"/9=J_$O>\=5WKS'&?/^%U MG_#K+A,\O!R_-^GWX3?I-Q@,U,7Z7?(KU(Z)TP]_0;X B\O35SN#=T9 MU\,W>$,C>8,O3I\9&T;W])CHRK$.ODAYBS=KSHS^UVU,*GW/G3.1\&W4;=>; M[@%\F"94;[.:+*' @E+P__KV=#N^W$N_?GSI)\]EMN@YH. >8 6V5#LMED_+ M];B>S'OI21V'AY["N"?N".?AO>Z5G\:ZEX^H\O MG]3O\.& >TS3'=OC-@R"Q]^\3WCCA:8#F@GN_?ZC\QU1$)]RRO_EFR^_GURJ MRT\[HR$_^82M? J?T76,D2:\D<5_/\&':U\,\R7XX'\;IAA:;/19LQV;_^^O M7\RWSW@?=]6OIF%P6_X*W]_[ ^Z:NF:S 30%V/&Y->"V ?_WOEOL^43U^\P2_,NG1).SGW#EZ+Y\@"ET9OTW9^YW M^$0L^"S\N>*C'N%;QUCF8?\H+?RH:QLF>W0)#W.9=6,;_.W_\=&"CRF";2C5 MSNO%Q1]W*;$P-H;7MG$%"+S@$T]/2V60[JG'?4I*B,M['"&7BZ]?4+,^"VF] MH&U-VKS/'LCF[R?"' PM5#GY6=_%1Z/]/@T-]-F; -/P*6@DU-&EF_D)9N8, M]#&\!(W/'"R0M@EN$3!04J]OQP\.FPA,V'S3#HTX0^YZ)A?3)&)Q9K P/5E_ MH S>6W:@X!;3-H]KF"S677:8X!9N'<\( ;HL.T)PB^Y;>5.X3Q-P)_\4CN_* MOR0]_QQ JV8"*7YLB0<[!JG:5RVXBDM+$/UI&OA!S^2N)M&3IW*1RYO_E[0# MDS=#>Y]2VQ]*JS9^G'04/&DG3XL5"?+);Z*&HCL_)5YOYMN6RNIM2\T,OBV0 MT\"D;>!M9YC-K+PUO)GKH;4/9AD]C_#.\7?COAJQ:^,2$7ZSUAB5FN,QRI!D MQ,=(.2Z+C1%>N[$QDAA1^UFL9DM^DA@!GDYU\QC1R.#;@L>].8R(XW^&Y#Z! MB)O%_S$2_KQDKCLR[>S?'X%;HGE"-_E=WS0Y:XO M,( 1??UM=,<9?HN^V371DW=V$/? M$[?\A5NE&<^*?OT3AA'H1W\D+\=V=C%K >3P9WS9X&\#GO-:>.8 K-9#+QJ%-763%"XN6\N,+VE;3K5M"Q9N0UKT\\ZQ M^>B.N;^X]]VW#;$8+!R(\F74VJ7/">GB!G0QL^;LN!4QBU:0M#!?%O'2<:$U M$*(KWO7:7/==$Z.^Y40;ILULW<1E->&Y7/= M21<3>#XN:7R>+VDY5_*N 7[>""ZL#';E.7YWSB@ M'LCD;P8(,SWS@Z'EC#AO>X[^ZV&(F0_Q:6Z],M? ++[,3^ID3Z,IG/6"^9RO M/YU>;\#L6_;DP$"K+@O7NT10XNZ0N=[HG@WD(/Q\XH*C#;U"^^@,I2$#)]09 M#+B+]LW\M\QT:3V[7&I ?.)Q)!]Z+==E]C./F<#L"L"L'DNCO=I0K$$F8$X^ MITU*V*&T>N]4SZ'/5IWN3FQI\@G5335B&ES+-2SO-I*Z22 MVXYWD?:0A&9;0DE B==D7$07 E%:-,A#K(SL1=Z5D721=)%,X_:U,7VCU[L! M?>BJ85J^9[[P\3Q] M@^>+#9G:1C]:I%J>>(C2&*WH-CEBG!D4NR.E?"T#$/6J&36(S.-&_N2#4V/67&I MB_@_[A+V1A@5=&R>AZW7[_4\BGS,&X2CD@9=]P=8:Y(;#UZ?NSAB+N_CN+YP MY0T>F60L.B#')"5/W&.FS8UP2>"X1"+][0]Z_I,E*6DU]^A6<_=6\'.&!,Y; M;R'IVZ+T[7PM*&N21WD$QY%'D#6YHSR"8YAERB,X\-FE/(*]YQ%D32HHCR K M>019DPRL!.'84Y;@\$,L4R]^3+-.$?E]1N0S)PT4D<]@1#YK4D(1^=U&Y/=Z M -+XV# Z-F:W&QRW6*AZX>[L]>R*O)2EW.CA=5,Z1\?&D,)E0^&R40ITN]I& MQ\:0\NW_C JR?,WLFC-21%)$LHA4&9U0^(@GGS2?BEKG:.-GQ;KIY7B1B8WGE'Y/N12(;B,I%0FM'MC*;4;L;DYG?^] M%X++B010(;C#*@1W4&)'A>#R4@AN?V)7#\3NO.,0J]TWJTV(A.2U"XK$! ?> MZ*X2VG>Z?1]FB^$BVD&ZZQVD.YI7V@N:D;V@NYEOVM6Y_5V=.\K9I.I-N9JO M!;COP>K=CF.Y&P_4QTNJ$X_=]OQM\RQ?XK'[X[%;G5?BL9GCL=N<;^*QN^2Q MVYQ)XD6[XD4;G\6(W3:(%^V"US:VY9TTB!?M,[ZWS7DE7I0Y7K3-^29>M-/X MWA9GDGC1SN)%FYY%JK>[ZW7/[7@GM.ZY[W7/[VYM M)HD7[7 =;:U9]&U33>$/^.7GC_95; X&:@/25U,XU7+I_#-\&[82?A4UB^VD MMSF$ZU(:#7H'OZ[0IL 3I,3,5M77*[0+;_@3!NRG/*$JUKQAOH 017_B3??^ M@+O,<]R5AVNZ!?STBMO.P+136U[X[9*-?)IXB7>'X9^.ES9E,EL2OWMG9#^9 M;Y^AAX[OZERH/_N<&2#O7SY!)[Y^P1\:_M2$-[) EWL@E*?"_#?_K)4J9^7& M\.U"&S#WV;1//6?X62L.O>B#KN-YS@ N/*N?\\&%9@%HGO:Y^=SWX,,R7'DA MFWL-/NHZEG%Q\O4+T_J@F;^?_ W4\N1KAW4MKCD][1+U ;3XRR<6="_1,_50 M[,&;QGS/N=!>3GB1O1U4[99;Y#$WH\!CN3EX1-%)?B62WVVC/'07[6=5P8W^"S4]VQ'/>SYCYW/Q0+&O[W6MR#=S@50Z:#C9+#K%BV#:@]&='N1U1JFRR!B5\S]&\5>LIHK!&_9CH<%54MMC ],:?=;^XU^^ MXUUTP.()[9Z_:D_.@-GJPZ1\-_"Q"=VR'7? K,5D-#E(\6:DADX-R]35J_5W MV=GX<7_3N;[2VIU6Y[JMQ6>%QG;=L6U?7_YXNNGU M=OEP=W?3;M\\W.]NP,LY&_#R*@/^GTSTX4+/L0O:U=GEF58NUJK-%0;Y)-TJ M8J^D650]"0"S7#HKUB9QNKX.!)AR/Q>FC)YH@<_QA/1KQN'R M)U]+Q=-_2*XX;O K2>JZDFKQGK>JG!9W*Z?K8V1Q%8S\@(6KM0>;?TR3MO_Y M/[YXTE50<_K[21'$F5O6D!D&-!_]'3Q._AV\@[I#N0ZZ[[H@GU*.(NE3;'93 ML_6>09.&*U !TU;#$@AJ8JQ.U$N[X6L,V3,_[;J<_3HU;0$>Y&>-O3A2E.6% MQ@1'K\([R?UT.K/"]X+AA[=.P1V8]?<@Y!\^.M=/ MM_^M/5T_/CQUM,QMZR%-TX M0&;YOF7OT+I,__7L.KYMX%2JF=XF1SD.[/_NN)K7Y]J_0HS15+A4X[;!#>U= M;'J45U^K/;@K().!(66XJ6^PT0BFG]LG7^^PHI)6*14TO'X#C(@D8(X$ &*] M,Z*+ONVA\87%(HZ9I@X=E\%C<55\7>[08Y8(R4.5R,.BVM5Y:MVW;Y B$'O( M/GO8_%I'%DS/LC*[9' E8!!>!#4AA>BYSF!Z? RN8TT;N"Z8B:5U:EZ3,,' M8O"Z&:&#W?],V%7P/6E$IOG&[D*/.R9UF&!H"LRCT'HFD"+;Q[2'S\FEO4V$ M(V=2@6N91_$='GXOG[U@,+)8+)U6*N7S2Q."%)MV(*2.'<.4=57CT\1M*,SCEW@NE3NZ=(P5 MPJFG@NM8/-'C0]=YP8=A//6*6^R589KI L9M6LQGB\XB0SA'?]Z7T&,1R%UX M !WV=A.D@>M2W)9S!ZJGE5JQ4:\V9DB1EB)&\_&LL6$XVY:PK)>8E@WP6BE9 M[8,$),UQ-0?WVFA_^:XI#%.7,1Z@;[OBQD<[ 6;<.LAY<)^9;?Y;_IU.BX\" MOH]6(#[-Y,3^%9G>_ MLUM><';+Q:+VC;FN]B=SNT!AKESSA1>TM@\>CP((N()F/*LS?@F_/KB@G?:" M\_V?7'BXI5#TG;ZC_^+VY-P69B>5)9XLG8\']]%U7H ';RP8\LAM6XRL%^#1 M+&L!D S!PR2^-O7/<],(3P,?@67.3 F2=1V;:H *YH""SO>IB4V7<\^P+& MF0[_\;=&N71^(32/6WS8AU<-LHD*&N"*Y:/^:@S, M@EM D;7V#X,--((DML MP9.7,(OE^E1FT<>9[=\Z $:/^,I++5HTRM73(+(]S.^PGSF8(.3WFL7 <7!EEOIGFJ#-3M#X M[,@@YX:[,.Y#WQ4^)M]XC@978( SR$0O?^@&.>A 6S"YMZ6G3\KN$DX:F\TW MJ52WDA*RM2232B6W^3&;Z_HF?:-9OG:JI9PAAU$A)I!@F=@UD1L6O,H8,4R; M:/.F:7/']"P>@I7ZES.]KW[3\<33%7VK4"*F9E%5I=IFP(?D*T/RY3+)K&FI M=JQ:21 ICH6:0Y''Z#&N?V.U M$LV ;\&;QDN'+M>Y]*U+94T6@1+:!V@4Y%X3OM[71-_!#:!A/0FOS[S)5WEE MR?[*3?;RYN!M/A;D$L2'#W=B5X+&L'B.D#V1/<6U MB68QN2J9MAMT-1&MG%7@?U%V;;!5-!13^=D+;Y+A(,7'/<(4P4W%=.*ZXD/S%M3(0.<1 _D?4^$*+"HA43D5/5@U?3<%Y5 MRZ_@)$\\&/K6_65"6]@@S*CSBTCO+DAVNZU6(-?8O(WGM;5/.\&P?\!GGE^4*^6S MX+E>WY2%:(:R$,V6G1LY&3.E0YP+?@YP-DD-R M-HY*$,C9.,QY)6>#5/_8G W@X$RSH!VN,5T'9\/%$\!EL-_%^'[JIYMW%&#" M3V-/"H8O>IZ J8=?@Y4'= UT9S!D]@A72J"3'!C5,W[\[#JO7C_\]DQK.+?<+XH:?]&%N% 27#RCK^&5IBU=M(V/ M<+C_H'M:#D8W6%:*KR6=Y;[:9:F>VVS^>GX+=9;SV_6--;[1A+M5]U"\M^"_ M]I%]F\PVR43] 8R [<^..UHU?42V)$V#'K2$F22WZ>9E;A;),NG8V\R[ M3C\5Y]#D:B$RN["[E_D))*28.YNML::JX9;J2NJ9;_6<=,G6K"?8B!SK#17_ MHP8/K,&]$<$< ,!&7-G[V<$"0NE#0NE,3B"1J/E+_BH6%FY4"P)BP9[Q(&B7 MEZG.ZLS.]VCE#'SS!=PK%LR%U58XEI38%#5XR&PJ-SB?>1BED3RZD=P/][@. MEM;46*OU-6(>NV,>X?C_(4?^4HWY#AD(5>]G/6Z;',9FK2@ME+ M2XZ6*='<@+>2&5S[)&^/!7$QZ-:&##>SFX;/]B M"KDZ8S-;-YF%:S9X6!Q>+#QF&\PUA(:USDUC7G6_\P_LXX?RQP_?9F[%.7-K90WMT+6DNASRXH2@3X ,,@L'W7*KEOLS>(_#<7E+][ *X,/O)\]02L&P_=?^= M$#Q2DXWZO_69_N^>"?HN\W-D[O8=&TU[2E/75M7P%#0IH*PLE+0CR!9[Q-?A?@B2P=NT$.D3B@>V.C5%EDC,KY':-WY9$/ID4" M/CN9,]Z+W!]?)^IRT#I<)[)>V4C$FNZ[J1,TGAMX\]A EVJ5@A;^^'AQ\BG9 MK:3Q+\N%L$17S^KG*;T-/KY(F'59E0\ZRK2^B^#R-U#WDZ\=N4\#0. 2$M*9B[*'=ZVKIYL_6K?:XY^M MI[O6Y?6/SLUEZ[9=4'-[7$&GG8MH,>+K%AG')%6JB)_ MX_'!''NQ\&KU)GGA*J?TYOI\S$,4K"LN=-<=N+F&086U=TI]Y1 MSRPI(]G/G>PRV+/17-X^5N;8QTU.V6X@&5W@((,H+72Z=R?E2/8#Y$1:8LLL M;XUJHUZL_2R=?!V;(E*VQ><9T/NF'Q@? K,LED MDH]=X<@DDTDFDTP(L91)KLPTR3'GU^EI#T.NTO+'QWIVH"VNW3GR\)YKN2MW MEM$N%TM-,M%DHH]= )KG:#-L=5K.-ME;LK?'KDUULK=D;W,LO^/]7&7:ST5HMSQW M:)Q\O6,VH !2@B#4+K0K4^B^$+A-&[WSELVLD3"EGS]F$D@UU D3>,T3%[XU MF0M'%(,HQK$K78F2VHACY%F QQRC0AR#X&YYCM$\^?H//"O*]( 5O'!)%^ # M*_P;V8;E""STK[6ZCB\WM_WBGO9DBE]$(8A"'+M.E2A,010BSP(\IA!5HA $ M=\M3B%)1IB%XKF,)R1\>74?G!E(&(@A$$(Y=8TKG1!"HKBO5=G&D/\EQ:*NJZ G)FH> G%76EHJ[D7>>?_5%15_*NU_.N2R=?;_DSLY1; MS1$:R:\FO_KH=87\:J(&N1;@H$3<@O%N!&Y1/ON(ZO/:=Z9[C$BT@6G#T M:D*T@&A!K@68M@T0*UB/%51.OOZP7?YL"F@*BP$PB\OD_Z!,3YOKOFMZ)E?+ M]3\$QR^#\ *1""(11Z]5I0:1""(1.19@VA= )&(]$E'%H]-[3.X;_#%T;& - MMNFX,?) 1(&(PK%K#A$%(@JY%F#*_B>BL!Y1J)U\O8-OM3;K<6\4WS!(!($( MPK%K#!$$(@BY%N Q0:@102"X6X$@U$^^3FU&(&I U.#8=86H 5 OPF!K4 MB1H0W*U #;*WO2QWV_19&+;R;:6N6_9.[0NTW\]NXYO M&S@*2A+&;:2U%Q]U:80G1YT/XA9QI?OC[*++>XZ+[,)Z92,1:[H?D9-7T_#Z M*('%WRZT\/4J^'JZ8SGP\NYS]T.I5BEHX8^/%R>?4C0VD.3*6;F!=R>Z>E8_ M3^EM\/&%O#VL>B%K2R0,@*.??.V@%*@3U&TO/#EF>IS21DM.EL9\SP'!52_; M.*N9*3 \QWSK\$SN[J?&3UY*\K2>.MJ-K-]?OOA^<]^ZO[QIW6HW]]\?GNY: MG9N'^U1[C9TU#1CMR,Z?;(4_O3O\I7+J^+_E9?P3)3C2#EM*#U[M4>#+U7R/ M^%WKZNGF#Y#QQS];(.*7US\Z-Y>MVW9!37L(4^(?#E5Y ESWIV!RX?[ MJ^O[]O65!K^U'VYOKEH=^.-;ZQ;0YUIK_WE]W6EG3>QS/N8??MC,-X &A>: M:6M>W_$%LPU1T/B;SH>>)OK,5176A]P-_QH 3?+$Q[2Y0*XJS7O7<0WN_GY2 M/(%YL*R MD9_!SV4?T]8>,1N:>)5[Q.<9NJ%U6-.@=Y8;"C@8\&'S 64C+X: MCT48D4F+Y2BD2E+MD&"4?UM&AA(5(<<$=HK(!ZUOI_'C;)&&=!,MS@]Z-A:+ M>;K.*RB>_?O)F $N$/\,&E<>;@2G9S6EG%O!^<9:,+]X&'39 5EF%J>&:EI M "#5X\M+ST> HY&C!PZ8/ A4ZUK@,^=L8G9KE!LK,='DF>:[(CQ'.][KA+KP MP/GI"5HN>K?ZF,_2X%FPL-QLK%-JF=#K6+7IBNM\T.4N 5A. *S4/!X 6VL] M/[9$+U8)6KC3@1ZWV<WJ+P#3V^72+EE3D=B36*=3[$^LD-^MFNN=[3^X[LNC(;& MI"'^K&7#!F\WWVM.+S*!*SN#D+7SF8#Z( O3I\9&WY& M06O9!OYS/9:REG?)7'<$[?^363X_T73H!0S_$R94/K;$@UVL_*R4?N)2Q(GF MVZ;ZY@?\\O-'^^I$,[ANPEN+WT].*R>:@"F"9\)O:F/[[R?FF_?9]@>&XP57 MGGRMUPOU6NG+IV1WO[XK\%G!8M)"TL)=:V&IK+2PU-R4%E9!"YOG^=5"\L%S MQW7NF/N+JP0^,:ZX?AP\YW!]IRS";.N%F18*VG?'Q6+_XQJ]5[SKC?\*HD([ MH3V5:JG0J#7SB[BDE:25>];*S=.@2K-$> MM'#S+*E4*-7*^=7#^1QIN5#1UW_+5:YORUCN,QBUPS(H5;#Z/MW FK%IN%:H,<,=(YTKE=N5S5 M:K%0.MH%>@I,9SDP[0QA:$R2\0DP*2 NY2 ;<2?FY4\ZN .P[F' JE2:T(OJQD/^$# M3IW>J2]X("DR-$,4A1!RV] MW>D:WFX6S$NE0K66X\4[TC/2LXWKV386R.WCD!.^M M .\U'!_WFN^->V^U#^N0;Y* 0^C#_B3@R+*3Y0=4P_K69%W34D4[,/6G[3GZ MKS[TD+M"'N9X?J'ATK WHCK7FZPVFSW&NOH@'6A!8!)K$NL#%&L*LVXDS)K= M:MC6V*132>PL0-#.T(:"BB1-^9:F(W-"#V'G2$O7Y>'.,"\C60;R.$P.K3SL M:N4AD*]')5Z[W");*I1*TQE@N5F'(*TCK=NZUFUE8\AYCO.>R;\^7*+C^CQ6 MN_$XB,[A>D,9Q5T4LMBRS"X)3[E:*->IFC6I'ZG?^^JW>>93KA3JE1PG&%+T M)G>D1NZMBI8,1L1I"%0W#JK)C7PAMHYV>DY'B5@-*2 IX((*N(4C.5("J7G1 M/]I*F\-]C!GH FVEI?FGK;0Y=M>RNI56G\[T(L>->./&>>.^HM"UPGF1:C.2 MWI'>[3;\7"N4*L7\ZAV%GW.7LW[KV,\P+.Z LM8/"50S#Q4D321-&3$\Y&[3 MZB@AR?&2_1F+,_>.K>_2YSZG!5+20=+!Q75P"VND]1*MD69KP8K6R YVC8SF M/PM=R.D:Z0[Y'OEG/AFH OD>]'\Y]#WH@6SK.>GDGM&-'%'-'%7":G- M1IG\,E(X4KA=9:)6F],.66X4CCRR'-+A#'2!/#*:_QQZ9,?@:V4O=S[MJ!8N MCVJA!/J\D\#,,QR2)I(F2J#/F(W*7@+]H\M[W'4Y#CM8JP+,HJN],,OGVM_G MNYS1G=+,/3+WP6U[S./&/_'N1^ZV^\SERWJC/X?<_1G<.?9+;^Z_1XYI<:YC MNJ4^SPU9K=OGXEFQ6$Q;W9STKN$YFL#G:,SW^HX+\VX E5CBE64O12NZ>ZGI MD8\6VY^7!3HY>S[6Z62M !.!_U]@+M1S-.9I=\S5^PHL*R4 ,^B4/*GOBNM\ MT.5N_*M2\V*%^;H1PL_T7#WXGO#@G0%R=C99F^YE5L9RYF1O9QA+A6:]63AO M3E"M,^0Y2"YSQH"^O+.0FY9S89C%6GE0Z:?F77Z1Z$^9GV[1@BERX M?5H3I+]?OE SFSSC+^M]^,NL;+]7 [/D)9><4+>L8;=XFGAB!3_O!4[[+G#"_9Q4R, MXJ[=X%JA6FX62K5J%OU@)6\L?RFC)'"D<)M6^&VD*B9 M7X7+Y)ISGGWG%KPZ"H ^&+N]SF)P7KCTST]8^6(X0'XD#$?1N M'GK'\O> XG<9E[X;&X21WX+PW7/OH==A;SLA1-64HP-S@\&DD:21>];(+41] M2O7\:F0FXS[$G3;+G0S>,W73.PJ.I*5%V BF-RU>'^;C]!/W@)MSXYJY-K0G M8M)XI81QO^!^)#TE/HL7V+F6 M8K:3>'>E42M4SRGF38I'BC='\38?UJZ6ZH5:/<>*1ZY8#GEP!KI KAC-?PY= M,5J,R[K#%C\( +>?';T#]W>BD+NAD+&*Y2W;V),G5RV5"M5:CC-(20-) W>H M@5MPZ:KE0K%VL-E*VW'I2KNG]#MXY 2?K@"?-AR_:_']+&DA=8LS5SZWCP#Z%EDSM#'C5A0N;^ ^A='R,BSW_GLX]X%QC.NZ+8?8(ZYW8C@Z;-;-V4"XCP MP0 &5)PE&$#$ S8F=ENZ;\/REM9>0G PKC I-WPPT<@V17<6S]H?Z5U#84II M,I*^>^*\'(2EGC+P&=;5<:#9N18906/[UI7 M3S=_M&ZUQS];3W>MR^L?G9O+UFV[H$#NYOXR'6RQMZ8!P_W6J#;JQ=I/=.IH M!E:8@A3O4]@_=0+!SY)XH5/Y@4= MHJ^-"6/2B-I?:.@32S%S')F@]?)6&C_.%K,XI*&8%L]JO^5P?.>'ZAH;"=5- M-SB]&@O=5 .Y-5[36 O6ESZE:IFE:&^)5QH/T[1@ <&/+1_/ZF?+#LG4POW M7NK"_53O@9GF<^)V:Z0;*RU'@T_!M3MHI2^T:]O@QF2)U-1PP,R0VF9%;B/( MX3JO2F++2TOL8:/($@.S$T2!;JPQ5X0NV4,765[Y'0!)F?*T^/SJP[><3(]E M8;D!3AZ%04I&2K8[)9LXL.N8E"R%(;S/"")E:)ZLZ>C$7B1':9M:+"J1^13. M[)TO_L1?N.USL>W3Q+5Q+"(K26*'N]TG\PE/^Q6L+4S$S*(*BP6[2.(R71#L MV,Q4]LI^J9T&;F"LCL]6+9C0//746' LRO>3* M'JS$YVRV?*4CUQP3$=028)&N#*6LX0MRF0N3H< M\,CB'MU0[EJV<366NFO%EJ[?=,M'!&CI__)-EQLW]J/KZ%R(2T=,5LDMEGX6 MU>;YCK.%DFB50C7EYOX'4@>P'L(H?5<9Q!ZD8Y]=-XCG9&^FY*%"Q+6&UMW!AP%<_->Y2*'H\]P+W-S-OKQ MN) VWV$XBN%8H4B\12)ITA\!H.K1R@? M%(FG2#RYCM,LXIY[FH71^"/S&6<$0NC(Y%T%[4#P]AYRKQ=*%0JYY\"1?#_D M3HJ;)<7==IR]5B@VIB- N5'G MHF=,0O;F8.9?7/*T[$BU)V>[D'CD)Q"# 5 &>?(GE: \("Z:^9#]\7A#1[*L MEGF).[S(*%FW*>OVC0E35\4J38W1G,\=(*"JWG7Z'?# MK1O2Z.)9LY%?C:8PPX$1,76P*/S"8/QAXC00URYP,J>7H&5"' G%BLY M,HYVR YB%O,N_S.0R982R7LID0\]B;T/8S'OGU7+S4*I M-LW/3S\[$C"/0>OS?-9VEK:7*E7"]5ZCHL3*6X&/UG7XDEQU"W.7/F M/G;E+1(=G-#D >(;N4^]K;Q,8[[GC'G;6:3-;-YD%G84/\&P!<9;0I4BC-B9V6[IOP_*6UEY"<-!M MF)0;/IAH9)NB.PNQ]F=AUE"8KO6*QN)V'SU(V^B&?V;Y^@G7SMH0= %O$0;#(K[Y1-+4=>-8OZ[(KR< MA"7>,B!(J\IXT(P"/=@?^ MN;N^[[2UA^_PU=WCT_6?<-W-/Z^UVX=V>^:LT"RL% O^83/?,(%Q7&BFK7E] MQQ?@4(B/:>.,M%U"FTK_DDZ!SBTK8/#1W\'3E?N01#=D=1+>5,\2>#[U,D&6 M&4"[Q88"/A9\R%Q@0]%7X_<,HZ/IV:QO4\'3$%SKORTC'XF0ZQQ/.'ROK31^ MG"W2D&ZBQ?D+$(V-I'U/-SB]%W![_*6Q%FPOG0BTS 9(;^78A'HD "$ GOW[ M2?WDO<=/[0#U4G> 3HQ;ON9DM_:UL8IY[8!;P-5$WD%3?:%^OP:7WP@^QC,$ MU:^54B'=P9\9,MN,<&T$$USG5S[1F4F)XEI22JFYD.O^;V,_2 M2B'KEF(R]]#E?0X3\L+#&MQVUO,<\&^AXR!\9S[QE MJLRV3#]L&"@+6C>T9V;:&C"G^+ND[FY1?Y;H2""'*(8MB/Y:QE_^<+#3&7P%!YZ'?;V MZ+C8N6"!^P/IPH&?TI#MP<] %W)Z\,(QQ"MKF8M7)@S]+LY5R :II-6A M/:\.I1#,D#SN:0&W5FA6ZOE=*R(5)17=MXIN>SFW6J@U*OE5T3P4/I0\'?C!"QD<_"WW8]UD'F2ATDX^*(QO/SU^BVDV28,C+#JF(#55T MV7U%EPI5=*&*+@=7R6)C%5UJ5-%EBQ5=VIV'R__WY\/MU?53^S_^UBB7SB^T MZW_\N.G\-U5VV4EEEX+&WW2.^Q/E>1%8S!@/D0C^&@ '\L3'=Z9B!63;7>T8 MN7%PJC[,N 3,DA5BJN7?EBY2LLPM^[J.NDI=I:Y25[/:5:I4M-=*1>NYF+.* M.RQ1P2CMZ- %RRSDP>_GKLM1<1S]5XI;LFQAINWHTAX> M2>I+ZIMU];T,CMW)M.[.J4&S4SU>KLC1T>CTSE2D!0.**0_,^M)U)Z+:&]DV M-F2F >0X5 3YD$LV-#UFY;I.TG:G):DW"RAOIKCUP6U ZM=$-0/U4:*DP6)VDP"" (( XG PN ]4S<]4GY2?E+^ U?^ MCN.%/H?TE/O0-^Z*8$5>?<'_Y9O>B.!@13B@!8Q#7L @Z#Q6Z&RK [U7"2T> M*Q22&I,:9TV-6S+5C=28U)C4.,=J3-:8U)C4./=J3-9XP_$%RFBGKE)7J:O4 MU.:1NLS78&C';O-:1$#;L(H?;S:#/RY6+FI:!R6G:[-B^D^&\96&:Q?Q2%&&' M+[U:!:R%-'C+XWD@JOAN*:V!8[=QZ51%(&Z$\+DQ44:K)1[L4CDLG_4SVED@ M[[N3ZNT+;*\=EL>XEFNN6*C+L;'.0.O-%)-EM^1671&OO%6,"F\5Y]?;*C3K MS<)Y2@WEU5VNW112SA@D$;YF'E__3M":56A5\BAS3:19J=8I#$K02M!*T'@:TCO?3 MSCIQ<_?BD;PMTCQ=UWCJE:%GB?N,>@8>.:N38\7VP' M91**D'M$ROF1X)88+2%KMAGMQLYL+]7!UZ\1$5T:3-;*&-Y& M+O",XQ#G)PA/YP+W G59$]Q],?74G964<)Q+LTVI*-FV MW90/1Z$: B$"(0(A J&LO R!$($0@5#^])9 B$"(0(A B$"(0(A *+\@-'\] MIV7\Y0L/5[=%QYF1V2GW+7UC@AOQ&+!<"7I0X=XGK/,M3(^W55B9C)+JX5&E9*>"+H)N@FZB3\2"&7D M90B$"(0(A/*GMP1"!$($0D?BQ)(/FN-\Q^Q62,U< F0>4>2'#7-N02\-[9F9 MM@9 J_ZBWNL:W%-<-UW0=$I89'L.MEU59RQ]<),"Q>3>HXKF,7; MT9+2>(GZGGL/O0Y[>W1<;+GE>:[9]>425,=Y9"Y/H5D*F;"/3.X%L"E,?@\"[:[_&1 MBTM0UW$-F+"P;Z7AFR8:ZY>A&2*A(*'( MPB-)*$@H2"A(*$@H2"A(*$@H2"A(*$@H#DTH#O2H!VUZH^42D[Q2\"RQVU(^ M\$!BJM^8Q6R=:\S3[IBK]Y7X5$HPO<5RD39A4JX+K6WLOQC"I3,8!&[:1_DKE:HEIN%4JU* M[([0]<#1E=A=3H%5HF/?L0SN"H6'V\?45:L$E@E("4@)2 E(#P%(9QPROW-0 MK5>KA6JI0M!*T$K02M!Z$-":P6--JJ55=[T0Q!+$YGHO$^%N9G'WG0V#RP)O M=O9HEVO-0J5&&PV7VVA(<$N,EI U>XQV4R2TTJ@5JN=$1)<'DWULP2[M/M]] M!X]<.=^],GS3#,?O6CQC">\K=&R=C'<2"Q(+$@L2B\S,$8D%B44V'DEB06)! M8D%B06)!8D%BD4^Q6&M+-FVVSG?4-+;9^HKKR=D'[<;*M MBIO:CU,JJU6,4H/V6^=Y!83P-5_X2FO#F876<*,U[;HF%#IP%"*6EVTHV@++ MV_^NZV*S4"S3CA9"UT-'5^)X.076A?+_-HRIM.N:@)2 E(#TJ($T,[NN2_5" M[9PX*D'KWJ&5M@02WFYX2V <U%WNATPA+3=HA2#L$CVU&"7V/!7VSLR&[ M5&D6RN>KQA*.2#D);BF.0,B:\3C"QJH"G=<+S085"-[TANS*#&NG, S0;\U9XC:)2B)^%#L+:67 M9%L3*<>-(MP$0@1"!$($0EEY&0(A J%,AA]4NU-QS+FZC4*R6*+9!V$O82]A+!)! *!LO0R!$ M('0L!'#3^:YKD$%*=B40)A F$"8F2""4D9 #K<%DVK.W_!WKKE<;LF#^R92(T'G-,'=%U/GE"=)UIBL M,;D$N=!; B$"(0(A B$"(0(A B$"(0(A B$"(0(A B$"(0(A J'\@=#\%9J6 M\9)^ ML@Q7KJI9*):I7#%!-T$W03?Q1P*AC+P,@1"!$(%0_O260(A B$#H2)Q8\D%S MG)Q(!1WC'QU<"N,/&^;<@EX:VC,S;0V !%[U%_=8U^*:X+KO@J)3PB+9=;+K MY%SD0V\)A B$"(0(A B$"(0(A B$"(0(A B$"(0(A B$"(0(A B$"(0(A B$ M"(0VN. \ZPCJU@LS+5Q,ZCFN8!9O1TM*XR7J>^X]]#KL[=%QL>66Y[EFUY=+ M4!WGD;EPR8+9TOLZ$GO>083-7#0F9 MCAR9/LS/7;GGGDI6N76$6"Q7^8E[#-HVKIEK0Q?$=A*3!<@&?#8W6:54*Q0; MQ17S58Y(1S\2ZA[8C!+J'AGJ$G9F 3OGY_DME^8WZR5#CR :$5""MR5 >0P. M[Z+]'A^YN 1U'=> "0O[5AJ^:<*Q3$-64##R2F^HU9S-:YQCSMCKEZ7XE/I0336RPU:1,FY;K0VL;^BR%<.H-! MQF_9![FJ%:NF\ M4*Q7B=T1NAXXNA*[RRFP2G3L.Y;!7:'PJ3'?)B*:\;-7(]%0'EHUVMCG7F*X[@R&S M1W '#)4'#_(<#$D;W!;F9U;$>F]3$7_LLO=6TZ+XB8C^?*B9/RGQ\'87 MCY;'\+;URD8B-E_]*#@>8%6I6/SM0@O%O()O$*N44:I5"EKX \S1IY2%IF T M*V?E!MZ=Z.I9_3REM\''ZL3PU^#17;OYHW6J/ M?[:>[EJ7US\Z-Y>MVW9!&9&;^\NSU!H01OV[R=C>[GHW$S5@?/2ZL"E1BSR-8%K#/N.;?@%UJQW)3DU;;B12=%#U?BIY:=944?1%%3V%( M[S.B2 &;.2N>_%[X=;.UDA=?7GBO6'*J+N\RXL=$7^M9H#Y:SW4&FC/D+O-P M90CW"[R8GLG%9^T]SK_>_J$Y(8DM+/C,4N4YO5AMATV:2&Y;VI8-0^QOG\<2 MF1(D321-NROU?PQVJ)(Y.W3//O(\)G*9-;CPY7N3&DS3E M6YK(C7_'6M4R9ZUDL9O3+E/[" 9#;@LFV1Y_P]\YF:"<@\:>]DK,K["$YW9\ M0YF[C(G=66"HWJ=*VE=Z4]*TA+*D@JN#L57,.5GU?!S(T* MD@-_H)3HB@_!:3<5#6*VH;&! R/];^)%!,K;!>6XY,'OT#C\TK*-5DP =\J2 M2N7I-8_< #2I(ZGCOM1Q.XRI/'U,06ZTD6)#N2-"EWUF/T/+R>4)(;@G)"^R M3-8U+5JJ. @ SCR D#21-&7$')'W'AJM\\P9K4>7#YEIA'ZZLE0.GC2EZ;[K MPD"%)HPL5KXQ)HLNPXVM UX(?L75OS=V((]7O,=!^HQK)9;@13 MTU@Z)^>>-)4T=0.:NN5%%NIZDB]4J.<_D.3AW)F#N)R;5F']@?*9QG'27=#?3NKME M$I:R 3$WNCN?@RU'P98IU;KC(RUW\,C%%6>J2O);6I7DO9]HN7R_UCG0DH2" MA&+#,T2!^8UXH:'WBU1=(B^3F.J.XH,@CUC.^]%U7@!!C&^C'P*)ZD,H ME:U(*/=4];)8J!5S3%));4EMLZBV6_8KZX7J^73":&ZTEEQ+\B(.P(L@H2"A MH&3X99W&[!^XHQ8DJ5+O81%-2E$B:3HB::(0YX'6;'GT7;W/<-^[T\.^_N*> MW,$EN(XI-13?/%#$R62@Y)&-9.)6QVGI__)-E]]% MF.Y'&G6/<]O M;(04E10U8XJZI;U=YY5"HY)C325//W?H%!0G(YK'3* +BW>[J>G0= MG7-#?'>=P5TD@[(PB0+HEFU<,LL2#[W6"S,ME,GOCHN"NR="52HV"]5RB;9^ MD-)"/CX)8,49VBG6-X MLR- \H^"B9&?G$D_^3&0T4>+V1X _74HICLE8952-;^.,JDJJ6H6574[W*LZ M[2KE1E,I,8]RL X@!XN$@H2"$O,.:#?7,$C$U[HC[4.PM>MC:I[>4;B*1#5W M&P"[BFI?J4"Q4Z\7\!OD.3B_)+\R"7[BVMFYY\U:E4&V2CY@U M;D[NP'&Y R04)!2T['BL6[QZILULG;9X'18=)8^'I.F(I"EFK;9O5*9MRL*] MGGS4Y%BE#-54%LO[UF3Y8T155I'WI-2I4?4I#;J"B[+!VKTT+N42B0_?U J)&NW M=L;JMY"+.^K+);RE>3^J9'?7LWW?(10^"7/K.?^1/S^'6OQ_7=5C\H-0O- MVG0!A-Q0UH/3;=KHDH6-+IG0^"UOEFD6&GD^ )NB_H><4)[*[9BG=3ETW<;H M/Q:YDHI&E(\L0+8HWP2>M\2#72IOO!A.O5!OYK@.(:DHJ6@V5;2QL2H"YX7* M>3._*DKK 13Z/8#0+PD%"06M!QRX8\CA\V-S"?].5#.?5'/S(,U.DF" MM).T&GWG'\'CUR9\U> 6QN.C^=H98OTK]"Q=5@_ MB06)Q<;GB-82#]1E;/O#H<7QH )FX:$WNN4(WU5E1L*Z59II*],-)ID*5>6= MH&:>2Y$TD33MBIEO/(R9>1,TYUBVAZ['3)DZPA(OL9'J/5(.3IW>J2]X(#5, M")G K/$@X0L]1'BV)?.9+9-U3:?&?,^) M*BG'Q*81;!<%7.RHW)4GFE ML_IY2F^#CU41Y=?@T5W'0L?X"]/Z+MK/OWF.?O*U@T8$HX:7:'QM+#O,4O#N MZWJ O44P2;QC0(Y6%>&@&3E2PJ)S-?.M/B,UC0 MOOD"OA&B(-,EOS%A"C1>\:E<0O>V/P'U?(]_?/#5B ?CO]X@+\=!9X_A'3/ M&0>6_=AG,/8Z]Z6?#=)Q8^MGV@<\H $C<^7BQ:4B[_*OTH7FN.$781O!-Q\U MD"BFZ3 TF4'_O[,M6&B?2WP!#2#OW#+&2J/ 'XM:'V8P]-_^0P#&@5-@#Q8 MIP/'XKH/+,MP_6=HW#! 6@7>-&!_04=\>\ ]S9;G2L@*(*YA.B],P#W,+6CP M)0.A,'4E\Y;YPEU<\<7@"3@5'7C'V,N5SB\$!N(-V4ET[ J;7Q.X^^/VM%)J MU@."^ '>!WIINL[@8P''K\OE8H3Q HB*WA"\Y,;[ ) /$J8[?1R:H"/"X\QS M^GP( NM!/SX$8%9W-8(XW)C>M"&W)G"'/V:GK] M\11$XZX)7^]K#,"GRP7,M9P:PV1=#HZAFJB=O'&/>?#PY/N,W_K[[57XV@E! M 3&#\9&>JO?JH/; ;17H+%A9+M1Q)N&,HDCB^.&_&(%+-C1T^8OI^ (&#N4- M7@G:5.V5WV_OCHWP2]R9)H?L3[C==?X]>H86M>\(%NA"_SD:'M^8"O[;X MP&2*_$(3WWG7]9D;M7.V93!:QJ+NR$$(0? 5Q1%^!2)C63C'NN,.'5=.,T-0 M&[KF"_P5P5.BN("IY*ZPZ6FPX2T M^1#H4Q?D$2\%^VUK_]>W1JJ%0P/?*:>49"_ M]TWAP: BZJ<%=13YF'B5+M>!A,K;)Y'YG>8F7+G]\<9&OGG+%HCAICC+OK88 M<1>78N(I85*->X[C830SED,F I%0&&+YAE+L5/$'_!\R5UV $5+70).OK";^ M[=NXT(/( [>"?@OMF=L '-@X?(]8(>]%7<$%'?A+^E]CV_U'J_48J7N?O7!0 M+V[' J] +IR!":-AG&DMV05XHC52ZNN'GN,RD5K-<##"&[Z]!KV=.6X"P.I? MONFJ$M[864EW0C2#:VU_IK+_Z;PBTA6T5WPKRX0_%!O!KL.^'2B6@,7S'@2F0+<*0*<.>-F!ISRJ$LX;T-\!. MD%<@R_AU 4:E!ZS7DV/'C+_ A@2W 14"YA0.K9(TN%KW75>1QMBU-M>!*:-U M5PDF/6:ZXS[@(R4-,S&"8@Z09/B6%W#BB0_EV. +AVV:4KP-@&(/V%,(_>'5 M49"A_U+JL =X1<^'3T:$[QJ^)K24]I9(!I.8F@C%?-56"\U(\'[HQ:$[=#NON-!=0UL?K"J-I^6H"5@G M<#;F8W-H%Z6EF>%OQ/P*B>4F?/P*[C$8-.?5AI;1YIB&"38. T0ML%G^H VBC MX3]Z351^2^3US]!%%%(DSAC@DT1+\ON \(L8WXW(-H]&?">$/U)&!BE&J MX**F!\X8=,)Q9EQIEA2%$QU.E[,%X"O$4$)PX/D4V" M%^-+1CV^27IBDH0FX\: G@]XLBX_S PL6 %-@IP@KX=/N,%L 5C= XT[DZ_ M9FQ@ K=&\DQ%885CRYP#'WBEHIFZZ>K^ $8>D>A,NY2)@G+\8\/IXLWHW8T= MQJ D!OREG KX;(3!%V? M5\V8"$ZA)XO_0M%ZW5)I0T3IL$-SW!&[AL]9QV$ M"S9D3]9,S347R3OP1955Y"_7,\JI'R,"AKJ/!MX$31325([ 7_!!T@,*,C'XK 5<'>*7%/[ MS@V,.($+.W2$Z6DWMO!=>==E$"!'*V#BIQQ!%^!^]4!LWE<3E'$TE9?6_0O= MWW%T9#*:/9:/^)%UI@1[&69RX5XU@T,3-ZJ&@040AJ&C.$G/5V&4V'I":.I" M:3 <&9/$4DCP+BKF'Q=-V:K+5#.N)H:XW*K".L JR3*L$"2ZDD0UF60 7< M"9(.\N&9GJ]ZF!:QG%QAP_[)*T$O.(JT^XM[\G75&\JEXF?H-B^H%117/F<( MN.^J8E#A\HW6=>"F,'269ES1.@+KQ^F25,2T,"QL>#QKBE^O6?C MICY8,3MU*F]P+[FIRRI ?5+QO\ZW%!O*'%T_<30S>:-KIHJ"] 6!N "8C9G! MN#D1N]806+ 17?JS=#(_?G0G]0-?JHVQ:(EDBKJMS=B2@UP\*Q:+IY5%[G!ZM/'\I'&X M>?I9/XM#AMK&(RM\)&5H&M'^:KC8)!>0(LY14,[C]+/"2P.W/)8U M$ 7R0@XJ^IQ/,';#"J9V'ZZ+2H[VQK':9%:WA/!("HQVGBBU+1\ M!-E2!N]Z<>F0JXH#C(S\.PH% 6\=F/X@".#H0*'";W!!5H5<9+1'.D"C2=8G MP[=A>EB\Z61S,A]'9NC9P4JF#,N".LF\G0''Q4_O3'OB,#__!B%[EMZ0C HY M0@2A'H-CGJ(*E8 ?Y<-=9@^7'0OC9>2P:W_YQG,4AI%QFU.X!B:/#U!5D>[; M.YR*"1T=1[46')B. V\/7P#5Y4",N0I$V>EO9L(0F*Y$&?X&X!4XC],N<-B0 MJ<+D2-5AP 0'SUCZLC'YD;%W.=ZIKHJZ??;=!7Q&S/>.,(KCH:\2RQP).B+9 M*P'NA(M%%GYQ<%+P/>7CY'3#]W*]6L;9@J2$> >BGBL.&D0&=81@N22'GEH@ MLW(A&<:\BVNQ9]K5.)28\/75VC 8"KT_L?R-XHDKQ,F1CJ8,5RU H50.@EQ[ MD(OE8Z$(%N#=5%F5:_=R3KEQC E_:799NH">2O;S5*9$" EV<#Z3Q!]?>KE* MI0I1^H"):Z_U%H9%7+$./\# MVQ$J!L^3#0KP+W[U@8."7@2>N@P4A5@[?K4@+)&T^)A^S&1>D*WAB,-O0Z#[ M 6(Z70Q*R+$S[:&O+#J+Y9\$ C\'=UT>%^. $&#, 1?8-%1>3RZU29P?@.9B MSL?&%&A292;F+!AF%;\?I G*.A'N[S#T_\21CVV7N;$%N#R#<:B;(MP[10.< M$^V?H3I$TZ+%YB5[L>ZL#)YN*S=UQQ;4TH*=R5!@,+23^6R38>U"+/@V MH8CPU7#H.F]RX2G X#&VB1E@MUBWPO0[1;3#%U,V=9Q-IG, :$/S,1<:J9F$ MZ9N0J>]:%%@P!E&VR4C0R=JZF7[)GAF (HC0#KU$CW'LIQ7!:((H!;NO1&? MEY;M1!TOC+!M0=B3E;NJOV54^F]Q"(/4_J" 4=)BRJ1>&4=70^8YB1M3LK!G*1P%LFS)/F/SV'P]9EV_<8&,MD:%#K>8'A_B%:+S+8P MX;69&P5 W/A4RZE/MI(J(1-WF7;TB"C$@ZQ&/9[D9S/R4PGDQ[>G)4@.>YBC MG696G%<[D=?!NHZOKHQ_F@;QRL#X I\EA2(DOI%=B8S(FK&RK3AR69G(,9-+ M1]G)6*5:DC0Q7]L#OSC(6 H6*E,M:^0FX15@6S'&(JVJBKH,_3"L(!+Y@S)A M/-%DS)I/+..K+\3D#4&L(946X38*C_U"H9$+O6&,1/E3>'\0'':"VF)A'H_I M&JB9X3;@+P@3B-T'NV#>8:XX> EV9P2\1= M:*RC%/JTL755-9:2T#&]C^0.<5!Q0S:5@"E5$.=OK)@%C9L2U0V8/-W#7$Y7 M[D]0?Q5PV,,LI=A0AKL))H ]"J?ALKBR ]C9KNO\ ADTP&>$)TG71L5?+R6*(&Q'@XRZW]3X.0"(.88=Q@"G4.9O6]DW5T5M6N[1L M@,T.W[@EI2 ETE!XQZT(X$>*FS$&C13B$:X-<2,J0YYZJ!42C>FLB"B7>9E' MEU,?G;H2)9,H@L2*9+;%%L,SH>LDDEFFP8N%GI)\(1$.IFSZ3)LY8?*"]/TX M[_1FW(&X(1F'6J,$RT0$,35$%L)&8O%KG=C2$\ 8OFO+-JY4606T)]6L6NPC[B>:V" ]]T;91S; M% &:.2J;2]TOJ2UW96XX:(0[J[%Q5ER<0\CPNRWWO&.C'\;?R-CWJ0(Z?#QT M7!*1CX7@6K6WU,9L9B;#2S"<0 L 2P'*1BKVHQ*K06$P H]QK6= M,$X&A5& MZ>5["N'HJA)$M)-PTA2 N0_+H2CX#/\ L@,@.P""=6,'/H J61('(8S?X Y' M'X^H I;10VH:5H:00219N[6@.>!3#&0H6QJ"07"\!5>Y@" D?@^&4P$U3 AP M.UE0I1! >O@$57QBXPN9I=-*P%BBU_=<4W8<^5V8?QH(CJ*LT)N9DB&E$M@4 MTN,S0/DHI\^7U45B=!$7;N4WXWSXR*.2@;V@OL8\<49@AQ;_K227 T6=VA*0 MZ 3\9HW^'6XHB)+P9>HF3CJN2@8D/BX=X;0FI"0@FFE MB>TH2,L\C6^MB(87E?N=_DI3CC:]JR*LN,=9;J97_<$+HRXQU6]YX]DLD_QI M(MUNZ=S&?&=[GE.VY[K9GILK$OINYN>B29T#X]GZ_,B\;>R_H6S.]3,+@ZE9 M*'\S"WNO)Z97*^&A;*GE,WA"9/A%QZ8C![F'0V#$9Y%@%4ZVE2V8U"< M17UKX#8"X;EJ)T702KCU86HK13PC,KE?>9QE>3;//9SK';;[T-EOR(LO8[3X M(:P$<6.CA8%N/H(W>E!Y"%.B-Z,0>A8=R+;T9N2L:?%IRX;K& ]41_Q8S'3! M(@5(A,W!_PF6L"?BV[(9Z=-@K%I>IK+Q.+!@9\31(W1Z0/&Y&[AE*M3KN!,; MB:0_@(_Z9C'H6%L5P@M:CJ+:,E"-S8^3(F=WCR6V+D>;B%1ZH72V,/5/!K.A M?;PY%A&7"4UJE<^+NB&?$W0\V4_5L6C+=!"MDTS7%+].>QALBS(\,4Y7@(&0 M*9"&-C*Y912T%PIAE*T1C+3JPL0E^+3)F0":K^K+Q'<2 M8UOF(*C!-'E'"*5Z,)&81@OO@HL&4?6DJ4D3Z,(V-7#A)H9,R_4K1ZUR' M7\5&(4IQDYD;S!XO840K!/ 08&PR>BF#G^,0PSM5Z<)]=$'D(LBY&\^5; W? M(=A('E]EBKU&CR4J:%]0%LT;19L?)CF/G9+*\LLQ1*:SCRW<-2]<%(A "Z R(Q>7#^(8#F1;K M^A@Y4GHKJ_/V1@$;4K1AHJVP]MQ-^T'$:D;*N%JX(<1C;P BSW*C:;B!9#H- M/ A8:$Q>#^KHJQRI<",LKJQA_!QW*^.2A)"JBT. &U*#6 EV(TPTC]Y^@)M- MHDH2F"^K(I$2:(/Z2E76"@/5.&K%1.,A52+BQC+V+A4VTF,,]UY-ZTIJ[DYL$T&"&44LJN=+-H#-H'.-MC:%<5_\(EQ.GK^>/ZZ?.97Y''(1B4AA"=T9K^#+M25NJP"\M(:2A$U0 MY#&;"T@BUI04B9H]B7>89-E!*>@DG@8VV(H7"F%:^LF$,A88S@F(NCR74#R" ML<7BDL_\H??/T+EI888Q6N.53@T=PF3%SR(L1T<1GI;GGD582CF+\+>8R\7" M;J&$H''8,!I?QO?K*$Q0N$SHO-?218EM5+=.5@[=2/8+=QNI$BH]"65!MGYP M+C1JO]RZI7A7-SP]1"X'R<7UL$H9"WUPM7PUWDX0SR@+5@KEXE^\9IBZ:2L' M+F!%13?.S'&P+DP;H-)DD,>Y#%-S,3,9;YY M^G_-7(Q$(";*,"NI_;Y+U^LJY<:T?+2"4O5A.:3R;A&/Y\6K)RIDD@7% M@B :1BM!D=1:!T8.I.>%;IYXOS6J9!\&-I9.HS321B4: MCBA#F*U\CJ ME<.(KH=QFXF@?YB8-/=N@%;DM^/:$P&S4]='>_483-!I.&.3!\G.73?3^]SP M+6"Y+6@B;&%<0N?Z36WL_@X&]%**7' 7 MXEH58P2QXR:B\J;Z>#Y4^9%W8*,0D"_3C4E_N@@EMTWB*>>RGUVYG?/W$Y@_ MG5M6<.!Y]'9YJ'&)TCU.*__EC*BZBG)$3V1G7"UZ;7T\;?1 M0>Q3K2\TL\';1.*!9ZFG-5O9;*L'WQ0-VZ)-P0]WIIQ+VAK+'#-E#NEG,%F. M:4QJ -@,N;\RQ%&%? E="]J3O1@CH\Q;N5!3=C$;E]E;T9-U!)+1_/ZF?K#T?IIW/V=BM)]58S1 # M U63=R=IJ/K]&KEHHB):XN>D?&U%CL9 0&J]+[6>G=.9V.X]+JV7_@))2=H$ M1@3T*,K2!6(E,^MD(G"QH.%_'X\32M3KR53IV54-5TY^;:3D>=:68#7K%-J, M.<:[1:5MJ0%QG3R"XFRN4R8Q/6SE8K6@E2L-^%&K?9RT M\HEXR=1;PQBE!!)C<<#W0LR)"E&G&C'AA68N42]*/G%!X=]9>L%X82), M?)TOV;-G9:$NCP.%*6"9-@";V2 Z2X5F=R(N/E*+9ZMARB[&S4SG)M%T-P*5 MGGX5+D2MN?S4DAEJ"ZT]_;P.TIWE]B.U1>Q.UDKQ!79ES9Y\&Z4WT'HSQ61* MF%IFC">%%:.DL.+\G+#">;E1*)7*4YEA[^AHFO59R] L+$&S]8EP@W CB[A1 M:HYQH]0\$-RHU,\+Q?/SG.+&.KR3&.5^%?G'.ZDTQ"[)2JPL7$$M6S6H:)[)\B1:1S3.O?C-!!D%&YB%C@F829.R?:,(/W/F1D$7=XLR5K?>Q M'V^1Y(:I[),9=W3#S!M2Z^TNO#,7YJ^EZDR O#RZC@V_ZCQVUB)MU=UO@7Q, MI='&4Z0EYR@;>W1O;.W_^C;';99U5=_H>ZO]+=RCVFK_V/S&>7S4::D2I+)J M036MU+,I@[C>I3I:YE9MG/_0<8:@#)5R_>-G[2YV5B!6($Y<"?8KM=E"4+8K MJ#(2U1^4M=KQ($-9Y-N)BHJE'7NL:A9,'-H1E#5Y!8OB<;R]I\J.J\)*!I8L MQP)5X'W+FL5=/)O^.Y;+\[N@JHD*"+'3-PQ'[@"41:G6*0+<4R,^4C6J!&@< M'O0S+FFNJW("A:U.>S#K,!RJ\@MN,I8GKE_) M0Y^@JWJ\.+NAH,/NZA=FG1D>.]1+%V&?O*O>[N(D9BP9<.7[7 M:^'A@'\X,+'0#9V[=EX9R6*RG%E"4CG3;DVP=$98*_>''12(E*8F$W0D R7> M\$!#O_N7//K2D;5M1;A0+2LHCP_=$%@A++":P7DU\M KTQF"WS@ P^*KP1AT?>JIR6/0L53HH?+#+S4'7=X6D5X7HXZCB M7:QI_-+C4UB$#C[NVP"*SW#]N)P($*>@;!Z.,L,:&>CY8@/P;<"K MP-!'I6TU51OYW:$(:Q]!+_'=HH.+9$WA[XZCJMM?N?ZSUHH5L9>UDL-24L\. M>-.V?$JLBNM$&;5M:4:0OZ]49N]'^RH>K3FM1>$:W&H)\P.?S8W;5.IGI:F0C:)Q,-)6 MO#KO8D5L"L'10.IH+WF"NJ[[ S\JG6KJIBH\N\Q(/7%UO&D8W&J-V[Q234X, M7TL\V%L59]9]S8K",+$X=+J?*.\N **6:AC(6CCL1,<"Z9C:J!";S: MD57LIX\6PY,CN1'4H@_/F<"R^%AP19:W=1W_N9\HMJPJ)MDRG(8/,7C7*X2' M6^F<&V+,T^^X^XPUEM")M@*V7RX7 F\Z@-+8/8)9XZ+TTX=D2".#=[6!5L&% M+21N44?&*X,R)$IH!),<'4^@SB+&FM=,] O3IXJ.3^.=++<']Z75GI+5CKM8 MG0?/83"Y.MM8'D4:%R6LUH[GZV'ATK%;"I*N@* M5-?TX#(;I28IT>@7XRFE:08SO"V4:)1:C&4$!18C>RJ/6K,LUG7=*9!?<51PG\63SYVY4O/55H.AQ+.?3R MU&9YV)LZ=E3X6.@U7M+1L4-R(J_G[F# ML@S0X&C+\ [60U(GHD;GI\$PRRJS8:E:)[WX8AB\*41GP25.MY$2.)8"/)+0 MG"YZW@\J9,:XD<%!^J-2[N,3X*+#(V7+82WNZ&"]H-2X+ T_YE!!37 K\@-T MY9*)<=ET/%Y CHG7=P0?7\#D$;!2W8RU"LJ":N+_K\?:V;*-NT@WQRLR:_F) M6A >X4;+FS@H[&>IW*AB )#"VZNC=GSS!S&P]RLA=F M6CBNIT"^3I'#!/'.=(/:Q]-:)@_:6.&X:GG("1(_+)9O%Z>K+5 Y9O,I:E:JLT;#1L&6T*1JVU4LA3B4JI&]BQ9%61< M%.1O1?F_BPR.1I(/!.$3( 63XS,_ WXYV7"!2\RONY*%D9DA)TMT?F[!F91V M,+MZD,TU:%DYEUY@2ZD#?.FIBB[LODC.M1B.1S;TH#3(-,@KSC(WYGI M[GEXUS5G*0.=0R27A^,4@R@T=[2I:NZ M8;A8YL=,Q(T_[V2;:97VC&UYSUBV]Q212)%(D4B12)%(D4@=E4AEHVX=<>:5 M.?.'6\P[#W9S?3PRLOSWPX.++-960$%KV<9$FA.&*/$(>GYE"MURA#Q&?DYF M]\]+YKHCZ,Z3W#S)#55S(:69>$F%Z.MOH]B&6CQ(5Y9%^(F=BE^?WE=Y:=34 MC3WT/2$5IS3C6=&O?YK;TPEIN>B! .! M"H'*^Z 2KWE)93!)T@]9TDFZ2;H/5;IW1 X7YG'7PI-[$1]ZT5/6))'$#+,0 M3Z"5NCQ$'>XM? M'E6X"$JD1(H@F;L3;9$$ZLC*.[,R+Y&PYI.'RY(ZQP>MHX/IODT;(7:$S0B; M$5M-4%Q07%!<4'P'4/Q%E,7&.AI$4Y2$AQUT/5R$T1B+ W'EJV)A!RP>@^7T MO*"^PLO(O?%__&@G^/SD"Y7LQ6K\;XFXOZ1 7':LKL,+WXYC;S#)JW:FY[OQQ4B]KH6F8A M57L+!UPG!RL=ZGV5#1="G(CQ*^P M&F$U8L4*B@N*"XH+BN\ BK^,PO@,W>YEG#RB+2[=6;.0KV;6NLQ<VTCQ"A M%V9?[-"9ET4N>_8'F>>SC\0J5RVPNN-[7;8 TW,Z+0O_][H!*YB&IQ<\L*PZ M)%_520EN"&X(;@AN"&X(;JP$-R3Q=MNC7]=A0MTT9A3*D;".6.D-M])7$-99 M6DK#<>MX4ZUDH7.ACCM=3[W2-5%VM/=+M_Y&%_XH M][EVA1$WT95T;MIK7X;1E>U7D/Y\% )\_U8N=CLD-T]SKG5MX*VN@UZG=7BR MH77?A.4(RWD)EN,XZ2CU@=S=WZ(PCO->E+_97O"K O)2U_;]DVX+;"#+.#[M M"+MH&+NP[H9>HH@<%!+;762/A8\6@T3^0"?=HZ)](X7#::MGYI>;SL7 M$8:Q3J4CI^191R<";MH&+L0=^PNNV,WD8D<'H@[MFE< M1!C&UKACYV()6^^/)>-F&TOX+^2-E:IP4L&G,15\!#<$-P0W!#<$-P0WI"J< MQ+<7K0K7FBX)AW7B1G77UGF*=0BV=9X]3Z$2A5 >N? M5'O@!>[5,(R2:Q6-\OR$^#S!B.GFUJX[[)RV.F='FVG,"]_9++[S,,'5])T, MW-GNO)J@X<-.O661S$EW=J1."*4A484MI)Y&A>>61+48I7O$%[^T^'KG4&)C M3:->(=0=4Z^+A0;GT[ WM-(@*M9'W0V]8OGR4;+N6J-D3YW]93V:!^-[RPU3 M],:LRZ4Y:PDOZ--<]*P$.]:^!,$.P0[!#L&.;<8.4IG@'[1Z2SJTXRL[HDF' MJ+K=9P8#JM!9$3UY89X7JO<-I[\H#%G4FRGV5M6;U:BTE)GA0P?L Q55$&,Y M=O'SS+:SDC%1M"O*7R\"D:)FWZ?\:=#L_3M[$N? &F9F@>96W4[G^S>6.;(# M7'8AZML].FA9YA]@*C],F\@:;@?MWBF^7%IH^_BD9JWZZS?T^IV>N1_Z:('\ M9%O#""VX?R2AL_?+-04PPX%U@88DF)0__6"78&1-'3]/1G"W[#0),[Y\VC[R M:@Z;G=MHJ'I!:I.]Z[D_[UT#%ETI7Y'I]U>W=WIXVNMU%WCXJ,?V%.V .>;/ M>QTPB97O:_:5?=9H0Y_+QW/6^WXV?FI.R;LL!:SY*\VGX3Q]>QS#V[$:VY@: MF_V4XZNV_NJMQONJ;6A,N,/O%Y$;I2R!O1H;.I>@RQQUZX<2L G8!&S-&VK: M%S?M>V/76\YM3TDD/:2P9_[W6=[JJGY3E+,D9@L:DE:0RO.7Y74G_P:E.GRL M>(L?LS!F7Z8!R002*/AYKWN8";ZR<=$=)SH1[Q\=^K\W#83&6^60EYKW=]!M MZ:(0G>Y9%40/NVH70X\HO&/H]?8V#U466/QLM(%W:\;90 S"3*2G@VAJ0653 MNC?'$NK O*PC:BYNYM'LQ5C9B@ N0!8@/Q'(&!I=,WB?*\YJ +V!G/P&D]FV M!=$W$/X^I27) :SM &XQ0:-QK*C!]U\.Y?[+$^H[XIT7O.=2O?PBG1FW(Q.O MV5E6@E*"4H)2@E*"4H)2.X52S]&L16=N@,YC*-NQ&=2VD<.==:VMK=XC768RY9D=[&]T/]KAU M?':RF1%7H7.A\RUWV@B*"XH+B@N*"XIO;FZ>J&J2'+?)]G>>IU9(C).*F=O! MR)O--@2E!*4$I02E!*4$I78*I22JM>U:]79<.7GJC9.)LJ.]7[KU%T[P1[EN MLBN,N(FNI/-;V_.13"[#Z,KV*TA_/@H!OG\K%QNPD9MG'25)GTR0M7=%>^LK M2G70.6L='&_HK4]A.<)R7H+E.$XZ2GT@=_>W*(SCO#W>;[87_$I]VZ_M^T?X MT-:PC%ZO(^RB8>S"NAMZB2)R4$AL=Y$]%AZR9![R:C5,Y -\VCDF=B8B_&*=.D=.SF7B7AE'>)DZ.&NV;8X.-]2VD:"]N!?7ZUX\F(>)?/0" M;Y2.^-$X2K[:P8U:U/,(L-P6<-CW"X.C-]L16UOXYZ=^],,OXHT5-:4)KI$& M>V/G(MB&J2RGO=;)\8:F&0K+$9:SX=[83609!V?"+AK&+L0;N\O>V(UD(N*- M;1H3$7ZQ-=[8N3C"UKMCP;8Y[2S*:!JBK$C]-BG5L]FE>@0-FK0"08,&',+Z M5R!HT(!#6/\*I'Z;A*)77K^M-5V\#2NZC>HNF.]8/%%ZBB_+QBY,NW@)G4+5 MG&6-4VOS4U8!5BJI-M,*W*MA&"77*AKEJ03Q>8+!S0VN,@?,^+0G40+A.UO+ M=TIUMQZF^9H>>H$[V_M7$V)\V >XM%L61T*Q3:/8&:$((>/5AO261+L8V7O$ M@;\\D2OQM*81K]#I"XK;8EG ^;3L3:T+>'#6ZFSE'8.51+6Z:XUJ/77V93@P M#\;WEANFZ&=9EP=SE4MXC@MST6,11&CP$@01FG *#5B"($(33J$!2U@;(I!Z M _^@<5A2E1U?V1%-.D0UZSY3K%'=S,$B51EU?2](;:TK3WTS\S+@ MN>-$*=CRGMWW?,[/R]3_:[ >?O5#Y]N,>WZ]SG78.6";HM?9LQ1H^&,T F'$ MQR*+S["NZ(N[LNE6TO:[I[7J_GV=@:?'Z8>^^W#XY07-P:.VI8_%*IQ+)898 M",>4C]68BE?.4+FI#R;>]!E?(PF_V/$NYH388*EN;[X1TLPGKE!?!-F,;P M>ORZN-&IY?R8T7V.""@?*.3,8NCG/3@N1_F^9O_99[UG^JS'9T@#;$".6':: MA P/+8Y/CK^O@: 6=@XLWQ['\'6LQC:FZ68_Y<#5EFV]17Q?M7NGIIWKB$M9 M$'LU_@%C]2YWU*T?2L V[U#3GI]I3P\[>G+\/R6G)R\B"N^ 9(*?]WI[,S3- MS.OZ#"Y8%9I%ONTH$ %1B=CKQ6B=:VU.;^J#PO;!+C\+P&=*;08VM>NP+0NJ MQ9*12B[1ZBX?<+P^N*OG(< "24[K)-F##<]EO#5Z4#?HN*$>G0?NKQKK7E0+:G5[AQO* M9<8 M4N >->4C$Z[1YO*"L6*A0J7 \5KL EU.J>3!?!WPPZ%(_0YBH[ MGY.ABD3!$=:Z(M9*^#6=W?Z2"LYAJR>>'Z%#H<.%Z'#Y*LY1ZZRSJ:;&YA3# M/GF0OE=>BEOJGJ[N9NCFE+\5-&@J&HC[^N4LNATQIR2+Z26=5&LRHGI@11UO M:LQ.R$_([R7);P41\X/6\<%6^H=78CP]M;3-6,LVYI,/H6)DBI+ZZZR=-RV MBD?S7_\X[75/WEA\1'7%EM8&Z04J(C41T!?A: 0:+P'[>7#=\$)2[VRZ'$K0 MB'/4L[S8 E7?2WSEPNO60T7;Z66"Y/^&"?9'P>..@?'T530G_RC;##",*AH- M[S]=9E9#IV0U[,?*0OF4IW&P\M".%U:Z*N[:& MRG?;+/7>S7ZJ I5(./-008!@ITFQR U-4J M@[(%YX%7>$I'@U!W0UA<$":6NA\#0/&(W-"*0XLJF1$.J%@IJDHV2!,0=$\& MN BN2@JQ&J@(CZI!+!61Z@JT'QCLW*JN$+',!DTYLFZQ@CR2X7LB#$AI[V,/"UQ9>=!B<7L: M&^O97_AV''\>T ,SRMK_-5;17WKZ>?AFU=O2:7XTYX1A-2=$\O*0Y++U M U$!?=&OL2D>6*;(! !6%:?]?R/OFV($)?(NNB&[W:,%BNG!# "1 MP>('YP! ;6#$OC?R$KJ,D]TS:-I2 =F7UIV._@5"L=U_I]P&HWE',X["6P^) M)E[NMH'%TM N<%TM@B^0K :> T2#3..MBD$*\/5<^,ADI@)'@2K%>B1QG@\% MG('',J9>H-,J@V_!=,"!"GJ7-?!0;[OSDB%]?:6<2"5V-*$A$[TB^B7)EN?; M=Z0(!M;_I('B+?:X>.J)]0H?1G6NUWF3KRG?(?W4??.Z;:$H F".,DXY4R[A M;+%*D!O .C74Z@9O6W^,Z5+S!' &#$27X-,"-2F.0S]ED$;+9\!W7D#.I72L M&8_>D89R"W5?RK&]A54$#%^P)X+L(RC) YB17L);>?% LW+8["#U?3.@J_I) M7!F=L $_C^T)T1+\7($ H)Q!(BN\8T4=W] V-;Z1"RW''GO8/)4E5F6NR Z^ M82'<<>3!#O0P,P\NQ=,HG41EU@??AB7!SD$=23S'&R/ZP=\>_!/':8ZRE=%* M5NPK0H85"-QE#VC'^]Y@WS$B&<08(](^;V>?MJ-QJX^]?%X;,@B +@ @:@HM MVM9520^9!O,JNI8V@G?SX=]Y@#TW*E 1H!&:4&"5/F"SE]49-M4_#XKF^\NK ML<^P^H.PUNA'VB5W.0@3=>\H+"8=@]$.)*JM8S^O^#408T%A@MR4'=6Q@=<%+("-PMB:;YD1D'.2 M 0QOE/TAU:%:%G,4H->,6)D@*U;SE.NY0",E(Q=3AZJ6FAJ5O. S[<12<<#E MIAKL_=)]#GOH5,W<7QZV?N_P!L FN!^^L&>"1V"-95^SV*$I^TCK^:$]Q[N.)#'-#X/ MBH4 OH)FEV!M@#B)B0'\:L?*_<):1=S0^,?B*2;DZ=L0']*)#G[L]_$HK%+I MGD;XDY[#)*YYU:9'RQ;<#=AD#UH&1U$(72YA&J'&.4'&&,9#=1V%Z M,\2>GL"N%<>"&$8WH**BB80.&K!38(BV]:<"7DF_CFQ27P/8./T:@\1UM>+= MZW2."ZM@[=5VP[$QQ9+II;(94_G26'@Q>=CQ+5H4#N$%R+11/FKY1H.#,%ZZ M2@GDOQ^#H@'\(IIHU;$R)XCC!-@#RK#<8P"R3([_:D(+;_/00LD&+4''($\)/RI8"GJ'7DV+\,U5.!: MOQ3>F%Y1*WJ\UZQE!C2N(^RI/>@-Q-C.KU<" =IR3,*569 MB6""&VY&.LD?T=+E'('][G[L,2)\@6%#=RY!\]='^]X;I2/6K^,H^8K3L#)= MU8_=-,KT8Q"WUD3943REJ@VB<)2#!O_0' #0D*"$'.5\5F.95DE?'=INAE!A MF@ ]DJ, R6>Z\V=OOI^TCMM=;N]::LEMQNJ :Z6YO_ 5/T4V6T=J)E^\=4* M?R\=HI6?WXK.PUB4;%H5NW?_ADC5U&/IG!ZU>EA2?L:QW"D4M&8W)/ XC CD M$JH1Y,NC]=1M+] M]'AU;1K>\)$]<)&OUI4U+T<\G2N?9-$+*$MI.C+_AG(8/:$=TNS;J\GLVZLY M\#;R?%[6?W/Z%*&KW>@UGIJYB'7VPX,Q!+]+?QC?!1LX-D9\AIH^[I'V[V/?WU6&4%[PRZ]/['#E([FC B MF$[%4I=-KC.OYCKS2_@6\VO0:W1B'1YW6V>GFWIU>JOI72H7+(G4'V]_M *R M-WK;.:ML[[2V]@7UM-4Q@YG9_;TY.<+Q8?MX4[E!0PKMBKKW%'5/QZ=T&%%4 M.^'W#57M*"89O]>1^-^B,*ZFO\X(QZ]+R>L='[>ZO4WMIR=T+W3_,G0?+T3X M"^AW*^ 'S];SSCKM[6RQV:QJPX=2;;C!*Y!JPPTXA/6O0*H-BUG[,E&,FKPP ML71%XVVHI;OY"=(;H;&GW9 M:GH7@IT_U5P$O ML T X(T_:67EJ>8K[D#5@7!S7#?I3LND?7U?3Y<0HJHY5(V(RA#%+5V72]<; M^M6WG6_[5\XP]+."+3"SJWPL(Y55<#$9L@M7H,@6R95)'CGLY:9)5J0T_?@6 MP'$)T*""^!N0,G5\VCZI$=AS$$XS8+E<,GP>++N=;KMS.@7,,A5*NXWE2$>N MD_CK=)W$=_?X=^VUX;J21%0,^+%Z1'K,<]\/'?JB7$F32FB>!^Y7Y80W 6S* M9:2F[YM\ MG-&2*^A(71X!FY0S:FH5D 96:3F6*BT;5:7E&@4L'^='DK*Z.2"*6OUUV2!; MI%++4A%-.,5V<0JIY[19G*(FB+[%=9J$3(1,GD@F8('N#)ELU$6@8\FL6H&W M!D-5DS'W)D#7ZX^2:;45Z1?-#N0+2@E*;6<5I@V04@?-E%)9I'FW!)"D_BT) MB>8OMZ>#A,I],)3X\KDT!UD4^^#A%+[6Z>'QAJ;P"2T++3>&EE>8(38O+1^U MSCH;G8XK[H,M5LR^5OM1[I9NMJV67!/O9BQ3*9KN@L9/Q9SWBTC4IR"S5<[JY=[Q$\O)"DD MV2!+<%DD>=SJ]#:U8.L&E6M<&;1Y*0\27+2]1($I"W0R%MMBXE*"4HU:!LF-V258W,_CX U4M=)3 O/O%!ETE:9O2\ MU^J<3!?7V@SGBM"UT'6#_)V-HNMNZ_3D9$/I6OP,VZZ[_:8"%=D^J6ZV._(" M+TXB&TLY[ICVMJUFW]:Q^HH*IQ$8./UY"7W7I<2='(L2)^0MY+TD3:Y9Y'W8 MZAYN:@L8R7&6Y-:U1STEQUG00'*<=S>L/6>.LQE3&-RJ&!L/8L6/ MF.SO:FNW3V'R_U22-W=;:0?F)W4"/3QL3ZM?I5:@P+R3H65G73PMT\4S4B/; M"["GVIAZUB' :QOEK1RLW#/O,HST5_A<=Q5U,@N W(^5\Z.;1A,@X[U?#MJ= M*JU:^$O<+FNR%7(N_&;]E/UKJ(W)D0B$6L%E354/1>?9]" WZ XLA+ M,("#'0K'CAW$:K;+=X(/LJ;J7$G,ZS;\HJO,;TF^R..VB M[YXRDT*2_B^SQXL?^>S@8P.Z"_0^V M!M'7T($5O\+2;+W.&_I$?W??O+9@2F?(S8SCNH6(8_]DKV!AWW$^__FULDQG**/;B\\*GV.D;I)X;LP M@G?'XRB\A?/PN/$X+AV>I70'9K;OTBC4O4BLL28:37?PX" *1]BH>:02#_YL M6^=6#"OQU;[KW7B 0N'$]I.)01B+0&9Y<=[N' ,Q2*FDL^H)XMDS )FGM#?< MCP/&(6 *_(QOH>[;MM[=.VJLZ3IV(J^/6EL_O 4&D51X9A F&GCX#/(;L"EQ M&(!'9:NT>. I!= 5T!SA-+1=ZV'-^BL,%:3J$G:!$@P?^A.X[T4*HP#6O:?H M% #O/(X5_,^]MN^7X8[LS.C#34H<(-\=&/BQ"A[SGRYO]0O%-^9>?1!.$R56J+7&Y*OFMRHDA)U->, JM(E802-I"(HQ$EQ53@G%TR MP?"<1/;P&M*7%S"@XW1, AMMJF?HCUX2\\GPJ%]@H6KALRT3:+/!(/@U2-1H\Q[46/2/-H);CF1IK4A1?Q(4#&V:A#&UJ=CN=[]]81N\_P!T4KAQTCPY:EOGG]9N] M'\K+*H+SH-T[Q;=+2VT?G]2L5G_]IFC16632P4)M"Q@4,,I_@,$.1$AMUH%( MD!\C6?WT@UT%U[,LZL6P=S'D*NUOD;Y\&V+X7GUY=_'^_(/UZ?/U.^OKN]_. MO[Y]_^DWZ_+SUS_AS_T/GS__$S]?79]?O_OX[M/UU6-V[$M)E.LA:&?_2D%9 M5I$_ ;6>67%@7<(A+=U09-;<[>S_2V\910:H=+&E+46@571#[?MA^(U47).( M&VOS$7;A@D&21G%JDW5!DCRV!PHD4]0'R8X:KA>39Q2(!7_]$GFW,(QUI9PT M HT/(/\@!46'!0FBF#5 %'[UO9\(EU8:QJWK'[*0Q<4VP$(S1!D8U]-0AP+ MYB)9&OIM/(<9$#$)3MF(J.#ZWLC3ZG_A25)EP5!6@0.;A[%!E0[HQ&BNLHAL MH?Y=?Q<;%:M;@F"+?B,M"F:$=>%'>"_U4=['<0A6%:Z#' [XF#9&2@KV@*;W M%>C21@%W8!S/A5=;RW=3?/SMP_Y!]^Q8X]ZKW,QX_896,HX\4F1P+Z!PPEG@ MISA)W0GJA^/00V .")KFU0P.XQ"Y,@"0'BA8:2D ,G\;'X?-DKT&R/.&W/C M#BTW1%,*-@4 JD[RIO@*6B6 $>2-SN=D\'XZO_H=WPO]%)]M$64DDY8U\/H1 M3 F/$A%0,$"O+*1HO$0?D C@%$788W'CP<-J/VF %9:)?S\ MZ?SRP]MLV,B+O^&)#, F!*(-U,"K@PBA5!C''@GNB'D&VKC&+F=J03(8J\C. MF8D.]1"S *0 \NB*POJQM/F)R!V$.,)CCUTKP1*N?S#P OLP"$8\"-PC($+ M_Z7C PO(^QM^;'%H*?'T4<4>8XL7N*#-1XCMM["'(/,IYA"YB<([V&=(.CO: MJ[U2]=!6? :%(9J N_Q:!)5-]0,7*>FA4R5*>^ M1D7:L>.:'PCFGSLUP,B>3'V%2E[U2\;IZI<&-Z=^8&XT!8V< M2TV_05QV:HI8J6_37P[KCN'.\Z<6EAI/0 P3@AT+3#)#L)4XM! MA[]@QV,]CO8<&+9(2&ZY'CGX$4U1.8&-DH>0 :.U1]X4*1DS][1.[_X#*EQ% M$;2UQ,*S1R'#:)$&VO-)JJMG7&^L2I:5OHI"5]&VBL*I($-+X[>L&[XMY[,> M1/Y6G[5:6.'2E;*+S__[_NU^]TR?#P#:98@ 3';_'2M/A!D=$'5*"G =BC$"46:QCT M9&!TTC J3UO0N/,E#_)3-[-53MQPF"HZ#57$[KB"(8"B(;AI6W^ 0H"\P/>( MWC7=(LX!<.$@';:.#-U9TRC>TO&^>*SL;_ LHE5FF:&BCW],B!#0M&M;'VTW M MO,YVA28G]3Z+H'1<\W%AL:4F-Z%1V2#_ Q>- H&@&0<<% :VEE (_:\2(G M'>%)H'%D#Q(=PYI>7(LP(Q\4GPH=5E@<\LVD02[X73U'V_H")DZLV 3#]\T6 M,YT'%$G4F7)KZ8_V5;MHKU)HYMX94CR% N0D-@BG"7%YF+-&,AH# 4%\NLV:,Q3[$E[5<0]R(B 1!4VI;?RH3L7+H!6 % M3AK'CZP-T/(&+1&8C/=H>'W,YA ZH[T$=VZ"S:B<7_(^C,R%5[[846*];UGO M 3FL[KDQ/L^# '=6]GLLG\MU._O_U!S.1!\P9T9''=XJA^*-QG=1$G">"]+M_O3P]+AS]-?IWIP";\DN/^9J;?)\SDZ\: MDEA43WG"L=' ]:%>S]DII F."6X6$;>&3>ZP=T$#Q1+;% 0R7O%,#CBH679B\GYT8A*HC\ MS"%]<$"2P![1L;(.,O4H^V/+PW;?U0R;:1'Y^(>UXQ]\%FS(VL+T,;]NBHE*[=H(\+">]]X#Q7*UE6YNL,K2,[F^>D*,^A MQ2#F7X9 H:7L=K1E$/OMS&2&8?"B0-\+QR6(6EI*P_9A$+:6R;BL).TZ4TF[ ME"@3A+=,3$@1]I@&S6-DA52F/%@SJ,1U6B!W$AMPT'-82'! !G:*1FG,Q/WB M,3BK)@C7PDQ!2CL<1QZL.9JT>+'[KA>1\Y*R?EF P+8G4>BYUA 0 9-4X0DU M!KZV_U__Z/4.WI <6_KRKW__NF^RC'@6^R;$@E*@RB%KS!,9*4D;(U+[KHV, M,<0"B6-TC+(LL8/<5T3N6XO0 P/:>)8E5Z ^*Y9,VNP; FL!\0NP@_-U"=4P M"M3*_8/+WWT0!D#Q3CA$9#(G&">PW'"HT'65>'&+PV57OS@=9^0SCA+@,L);2F[-S@5D,YRCM8&9U9!Q&J/\"JP-= M;] MM\Y-#M N24>IG_&P >F-- -/2]B+#CT:W1Z/;7(_DEH5MQD>1!U1>(->),K\ M]:)H2(%AV*4)*'L^!IU,VKK^.HE ST1EDQ7++&H'LBW4Z@@NAQ]VT.47M3$] M]$8'8G#)M 2856$: +'U,L HO!&'>!$OC<8V+!$CB;P?WD8Q[DW+U*ND '_= M.MO6>[JU8&,LIV4205@_=5!S9U&B+2X@,EHC;JX4F8X+.4K[B:1,5GBY3&H5PE18<23X#J4P%'=^FOEM_;BX/T&L)\=OH@%IO9M_KD&B"2:37)"86TP@[X71.[ V+.; M>!?BY74\O!,!TQ#4*>1:5NTNM28,@%4ZW@Z/=GM'N;@&R-H67U7H5?(PJ_ED M%$#+[B_AT2W?#=X#GJZ^&3%FTB%-\J*V-@']9ZR8Y.Y4]S#AHEC(RI$=W2-W=P7-I@^1X M-/)K9CH&^8A=H1NU?JLFV6*V SZ:KY7L99@\ M"O^>W*")1#!#A5)B?QB1G+YQ1J MLQ2ZKXTPZ"ME4D'(VTOJ4P$R/%A7C\$(Q-=G86^][IG)%(KQ^FV>?SP>*SMB M2=37J?!$73IZ#(S41\]MT>5M5EDZ8#P:OLT)(A]$!/D0W- \#C1K@6&7>..9 M#R1WH>5&Z0UY\LV]0KT;EBUH[:#Y4AB*!ABA%=6W?G92+2H)/TTN86KA9!J+B8\]R]G(8 MNCH_6J/_;HO'S\%-:!*5OL#1!K,$Y>>@>/&R=VKR'TK% 3)NP*&HA*[@>IB MS&',\W=7UU\_[[/ -4+U(.?:1+AT3IB4A9XYBSQS+7;-S7(G DTE=L'MJ/U] MK9)DIELT7"=KOP\0 5=\\1]?9'#I](^B*GD/:"_1'QW0S<^!%F'N>0X$]&SUD=@=YXKU9 M7003A2/RZW1_A/_GM"?B]SEA$N#8O4ED@5>Z>=LE!GC:L48W5OG6!!BO\"5= M(*>+%N7U D1(5A_ULLQ.+X(-G\%;!;;.2\6?^[:.3W-J#!>$2/LH_590[F+? M=AQEF*I)&]!7Z\U%B(KJ5%QL00//\_THQTG?EU$>>]["*;%FQQQ0B,RC1O2B M/-;*X=35"AUR,! M0KJ5E<.PN1:'W8^-C4WP]#"EZ_BAW U9\[ MKYDS8CL%O+WBAWTR,S/G)4[,SR[_ #K[W==9ND;EKA&@#F;;):M0OGK[=)B9 M!FFNLS!WL5ZQZ7?.EZ0FUA7N7L,I")%, ;8Z 2 C.")#X" @.K^I2>':4>'* M$/D/"Y,M?6,?WG[8+VA!A4R8%4"Q6X*B26#T1I0P;E3G,GRJ**S9A'$EER#+ M9O>7$IWH+*EZU4-K'6AU:0PH0'SYL=),I0&VLM_- M.-[R9SKJE:S*6DW&*F@R4\45,I/SI"RA@3X9T_=S%83NZ"J^"J=%E1.EG.V& M,JZL_6 B]#]5E1V::XTYC>DK?ME%1LK@SI M$91&5*1;RG7*^0A0&:,]XS;2T6M=),_RNY=4C*D^J2J4FL&Q&<-.@Y M.TJ;X64Q07M:1:#^Z_O]+V\O+PNR@#91N F:47#13E[%4LITH%>4P0,O2@!! M6NP&L2,R_MFRU2RM3FMT*:F,#D/#NZS09V>W_/U4-E(P"X;*'UNF'@JI8Z[Z M3XJ<5:OZ4Q=9$W,CA%2V3V_/4>TMW@XP6O#O>?&G =]OR1-&. 9=]9A&:=1%-[@K0F#&J^?P-PE7ZO2%YULA4+ALD=K(&YFOOBZLOS9 M@Z =OR5^75]"J*EY<2\%+G;5D$L2%:4[57#"S'"[M K%V> K?8^'RK3IFH$Z M/;6LR+9%)8FT$*B[":1M+")8@/79?S$DWHZ\AVOEE\>9Q)I%+[PKC5 M=ITD/CM)J&-;9RTK R-@Z@PXDCL+:89S\.W=0L]B[/5Q MCETRSH1U;P;KIFOTH,##D8RRW-QU8SR@WODX GSA;@1J*H@39!XCY(@WJ>=2 M % 7@$BP?,+UW!"BE(-O(0BT-C98L0W MR_C,#8S,HF!&1VE+'!L2:[;_?$HU%?G$VGB(7TM5HLL-J/031;K_%4[IX5_G552T]3ZTRD#'@O; MV./T#B>,:^II8LY>7J.S4),S#X?H:HR9"43W8&:4A>(R0Y6[?S'E[F5-ITHS MSMH"U2FA6=-*L!P8^]!5G$UQ(]7WNO-+C8_54=7B4X7@W5.8N.(VN M[W*IP%0TY"A:]A@O)U=.36(FE2U)\9Y 2KI:I3-V/ .]*+NMF$8W=5DU0R1\ M4J,.A:7_Q, *70I/R.>A=,\I#K0!K5#*GHETSX0+KZL_,7GVNA2.E4S&NGA0 MJI&R-($7#"([3J+4,6"'1ZBHDQ-A\^\LB6_FQ!HY&"ET2;V\HI[-366U-X,B M]+S2NZR<7=3W8.>ZAJRNDZ7K/@Q2OXEI\R_#_S[/Q4 ,Y\MY83CX<3;,YN3X M_"+VGB2*YA:7U&'"4;ZO6TMFG_66N!<%S\-OL,JGRY.2YIJI?JS:+E7QF*O) MK^[6"8OQ[7$,[YJ_LI\J!X0 V(># 4OK1VO@W2M4A*U28]\'&OE:I?Z=>N]' M=3LO]=NL?>W@^^ENG]C;&]\\[?6.ZUY]H;M>L>W;V377+"N'<;24 M.K49M4R?T46ZC2W:G\SJ Z^]B4""N:B0LC(HY"+D\B+D@A=/(FRBE*NRMD?7 M$2H.>/*AM7*ML%X/;&$B!V>)D4Z;Y3K$X2"A:K%<+R/ .R%V5KA9>ZBJ>J/0 MHM#B3M&B)L%"&[BJ]J[]O%DM?BHN46\H:KI-QUC"LV1?#E21S@U%CS)S PPK M(3TAO1TGO:('QI1P%JH0JMAMJJ ;KUQ0//>\B ;B;F\7;6;;=0IQ)+KE$-?[I$5FY745QSWGN$HAEX M$4U%-:$!NBK-!72QD((= =H^-GBKX%9V&; ($P N]KJA')^_V;G@IE%&)[1L M7=USJLI#H8,T";$R?(JR2Y?>S&%0 [FL?+)C1X Q(0##72L-:MIW]H6^>.$U(!:*Q@<*>HNG*@;HF+.Y11A?5#LKXTW/Z- MJ+9X#8BJ+<^* .]LL$K7=:+09U9U@1F/Z158R[T,HRPV[BB1D(D]8T7*6^HM M"2"D=#>NVV90S_3 HZBI+H,]A8TD[+'UBX?7;[&P)5NMH18VD9:UAMSI;&K'LZB4*/S+"\?CUH!.QD]0 MU[*QB445"[A*4-8"LI KK8]\2MQ0R7O-&:@^*4H3;L*.RC9YS;E&"9QHWGZ M5JFWFH$-;Y=FO:JFX5=J/I.M+09V'^L>%'$&.8.M83036?/NCCDSRZ9?Y[6' MI=X?W()DKM]8 >-"?RY6]Z"6DHA5DLY5#R:[#*8'DQDL$UMNY?WA*(UH1BBY M;,.99!?6Q$T/2&+4K5FI8J0A&<:"E=G,9^+2=D)R*XR20>A[88NZVG(E9-00 ME)Y8IT=1TT'J3.-Q#UF*P9G!?84-!4Q"%-ZV-[P*C'=N&-FJ6*BHE0ZQ]+S9 MYNXFR/PYK7G?S(%DJ/9EJG=)V=:6'3QIZY[B>0>/8LZ@P0G33]<\7<4-4X0 M95!N]M1C'1?#MT$"][%>N9,5TBBC8-41J$S+&=^+,[2Z>G=1LJ3*&@-6L\OE MF(&$MDE\[YLB&X2=)-,TPR@[((K*<5Q_P?J!;I0"PHL=):AKJ?R[&B1''6SD MI:-R+^0UE[S6<@O]R9+^OOIF+Z>7ZF7[!R?M9*,2O&N]-2#-T) M-1VX9[6[TJI]WI+,*;4 F]'//*+J;-SYI/SZ=)/0POVJ2'&5,[)BT=3-V42A M0:V#55J46R1>$+
XML 41 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2020
May 04, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Period End Date Mar. 31, 2020  
Document Fiscal Period Focus Q1  
Entity Registrant Name MADRIGAL PHARMACEUTICALS, INC.  
Entity Central Index Key 0001157601  
Entity File Number 001-33277  
Current Fiscal Year End Date --12-31  
Entity Tax Identification Number 04-3508648  
Entity Incorporation, State or Country Code DE  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   15,429,154
City Area Code 267  
Local Phone Number 824-2827  
Trading Symbol MDGL  
Security Exchange Name NASDAQ  
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share  
Entity Address, Address Line One Four Tower Bridge  
Entity Address, Address Line Two 200 Barr Harbor Drive, Suite 200  
Entity Address, City or Town West Conshohocken  
Entity Address, Postal Zip Code 19428  
Entity Address, State or Province PA  
XML 42 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Principle of Consolidation
The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.
The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.
Marketable Securities
Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.
 
The Company adjusts the cost of
available-for-sale
debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on
available-for-sale
securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three months ended March 31, 2020 and 2019, the Company determined it did not have any securities that were other-than-temporarily impaired.
Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three months ended March 31, 2020 and 2019, the Company did not have any realized gains or losses on marketable securities.
Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.
Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs.
As of March 31, 2020, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three months ended March 31, 2020 and 2019, the Company did not have any transfers of financial assets between Levels 1 and 2. As of March 31, 2020 and December 31, 2019, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, milestone payments under licensing agreements, and other costs associated with the Company’s preclinical and clinical programs. In particular, the Company has conducted safety studies in animals, optimized and implemented the manufacturing of our drug, and conducted Phase
1-3
clinical trials, all of which are considered research and development expenditures. Management uses significant judgment in estimating the amount of research and development costs recognized in each reporting period. Management analyzes and estimates the progress of its preclinical studies and clinical trials, completion of milestones events per underlying agreements, invoices received and contracted costs when estimating the research and development costs to accrue in each reporting period. Actual results could differ from the Company’s estimates. The Company’s historical estimates for research and development costs have not been materially different from the actual costs.
Patents
Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.
Stock-Based Compensation
The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is
re-evaluated
at least annually and the forfeiture rate is adjusted as necessary.
Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets.
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.
Comprehensive Loss
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.
Basic and Diluted Loss Per Common Share
Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three months ended March 31, 2020 and 2019, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive.
The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
 
Three Months Ended 
  
 
 
March 31,
 
  
2020
 
  
2019
 
Common stock options
   
1,728,112
     
1,367,077
 
Unvested restricted common stock
   
—  
      
52,063
 
Preferred stock
   
1,969,797
     
1,969,797
 
Recent Accounting Pronouncements
In June 2016, the FASB issued ASU
2016-13,
“Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires all or a portion of the amortized cost basis of a financial asset to be written off when it is deemed uncollectible. For public business entities that do not quali
f
y as a smaller reporting company, ASU
2016-13
is effective for annual and interim reporting periods beginning after December 15, 2019. The Company adopted ASU
2016-13
effective January 1, 2020. There was no significant impact from the adoption.
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) - shares
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Stock options    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) 1,728,112 1,367,077
Unvested restricted common stock    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares)   52,063
Preferred Stock    
Anti-dilutive securities    
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) 1,969,797 1,969,797
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity - Common Stock (Details)
 3 Months Ended
Mar. 31, 2020
Vote
Stockholders' Equity Note [Abstract]  
Number of votes per share that common stockholders are entitled to receive 1
XML 45 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Cash, Cash Equivalents and Marketable Securities (Tables)
 3 Months Ended
Mar. 31, 2020
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and available-for-sale marketable securities
A summary of cash, cash equivalents and
available-for-sale
marketable securities held by the Company as of March 31, 2020 and December 31, 2019 is as follows (in thousands):
 
  
March 31, 2020
  
 
  
Cost
    
Unrealized
    
Unrealized
    
Fair
  
gains
    
losses
    
value
  
Cash and cash equivalents:
   
     
     
     
 
Cash (Level 1)
  $
1,668
     $
  —  
     $
—  
     $
1,668
  
Money market funds (Level 1)
   
63,532
      
—  
      
—  
      
63,532
  
Corporate debt securities due within 3 months of date of purchase (Level 2)
   
1,451
      
—  
      
—  
      
1,451
  
                                 
Total cash and cash equivalents
   
66,651
      
—  
      
—  
      
66,651
  
Marketable securities:
   
     
     
     
 
Corporate debt securities due within 1 year of date of purchase (Level 2)
   
320,478
      
680
      
(261
 )    
320,897
  
Corporate debt securities due within 1 to 2 years of date of purchase
(Level 2)
   
20,966
      
39
      
(43
 )    
20,962
  
                                 
Total cash, cash equivalents and marketable securities
  $
 
 
408,095
     $
719
     $
(304
 )   $
 
 
408,510
  
                                 
 
  
December 31, 2019
  
 
  
Cost
    
Unrealized
    
Unrealized
    
Fair
  
gains
    
losses
    
value
  
Cash and cash equivalents:
   
     
     
     
 
Cash (Level 1)
  $
1,772
     $
—  
     $
—  
     $
1,772
  
Money market funds (Level 1)
   
44,925
      
—  
      
—  
      
44,925
  
Corporate debt securities due within 3 months of date of purchase (Level 2)
   
—  
      
—  
      
—  
      
—  
  
                                 
Total cash and cash equivalents
   
46,697
      
—  
      
—  
      
46,697
  
Marketable securities:
   
     
     
     
 
Corporate debt securities due within 1 year of date of purchase (Level 2)
   
309,365
      
220
      
(40
 )    
309,545
  
Corporate debt securities due within 1 to 2 years of date of purchase
(Level 2)
   
82,767
      
39
      
(3
 )    
82,803
  
                                 
Total cash, cash equivalents and marketable securities
  $
 
 
438,829
     $
  259
     $
(43
 )   $
  439,045
  
                                 
XML 46 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Liquidity and Uncertainties
 3 Months Ended
Mar. 31, 2020
Liquidity and Uncertainties  
Liquidity and Uncertainties
3. Liquidity and Uncertainties
The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations.
The Company has incurred losses since inception, including approximately $36.1 million for the three months ended March 31, 2020, resulting in an accumulated deficit of approximately $259.4 million as of March 31, 2020. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company’s common and Series A Convertible Preferred Stock.
The Company believes that its cash, cash equivalents and marketable securities at March 31, 2020 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.
XML 47 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation
7. Stock-based Compensation
T
he 2015 Stock Plan, as amended, is our primary plan through which equity based grants are awarded. We ceased making new awards under the 2006 Stock Plan upon adoption of the 2015 Stock Plan. The 2015 Stock Plan provides for the grant of incentive stock options,
non-statutory
stock options, restricted stock and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the Compensation Committee of the Board of Directors. The terms of stock options awarded under the 2015 Stock Plan, in general, are determined by the Compensation Committee, provided the exercise price per share generally shall not be set at less than the fair market value of a share of the common stock on the date of grant and the term shall not be greater than ten years from the date the option is granted. As of March 31, 2020, the Company had options outstanding to purchase 1,728,112 shares of its common stock, which includes options outstanding under its 2006 Stock Plan. As of March 31, 2020, 1,085,220 shares were available for future issuance.
The following table summarizes stock option activity during the three months ended March 31, 2020:
 
Shares
 
  
Weighted
average
exercise price
 
Outstanding at January 1, 2020
   
1,461,987
    $
  64.67
 
Options granted
   
266,125
     
90.75
 
                 
Outstanding at March 31, 2020
   
1,728,112
    $
68.69
 
                 
Exercisable at March 31, 2020
   
1,025,465
    $
45.81
 
The total cash received by the Company as a result of stock option exercises was $0 and $0.1 million, respectively, for the three months ended March 31, 2020 and 2019. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the three months ended March 31, 2020 and 2019 were $68.71 and $101.08, respectively.
Stock-Based Compensation Expense
Stock-based compensation expense during the three months ended March 31, 2020 and 2019 was as follows (in thousands):
 
Three Months Ended March 31,
 
  
2020
 
  
2019
 
Stock-based compensation expense by type of award:
   
     
 
Stock options
  $
  4,846
    $
  5,901
 
Restricted stock
   
—  
      
121
 
                 
Total stock-based compensation expense
  $
4,846
    $
6,022
 
                 
Effect of stock-based compensation expense by line item:
   
     
 
Research and development
  $
2,078
    $
1,877
 
General and administrative
   
2,768
     
4,145
 
                 
Total stock-based compensation expense included in net loss
  $
4,846
    $
6,022
 
                 
Unrecognized stock-based compensation expense on stock options as of March 31, 2020 was $44.2 million with a weighted average remaining period of 3.0 years.
XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 87 212 1 false 26 0 false 5 false false R1.htm 1001 - Document - Cover Page Sheet http://www.madrigalpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.madrigalpharma.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Organization, Business and Basis of Presentation Sheet http://www.madrigalpharma.com/role/OrganizationBusinessAndBasisOfPresentation Organization, Business and Basis of Presentation Notes 8 false false R9.htm 1009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Liquidity and Uncertainties Sheet http://www.madrigalpharma.com/role/LiquidityAndUncertainties Liquidity and Uncertainties Notes 10 false false R11.htm 1011 - Disclosure - Cash, Cash Equivalents and Marketable Securities Sheet http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities Cash, Cash Equivalents and Marketable Securities Notes 11 false false R12.htm 1012 - Disclosure - Accrued Liabilities Sheet http://www.madrigalpharma.com/role/AccruedLiabilities Accrued Liabilities Notes 12 false false R13.htm 1013 - Disclosure - Stockholders' Equity Sheet http://www.madrigalpharma.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 1014 - Disclosure - Stock-based Compensation Sheet http://www.madrigalpharma.com/role/StockBasedCompensation Stock-based Compensation Notes 14 false false R15.htm 1015 - Disclosure - Commitments and Contingencies Sheet http://www.madrigalpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 1017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) Sheet http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables Cash, Cash Equivalents and Marketable Securities (Tables) Tables http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecurities 18 false false R19.htm 1019 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.madrigalpharma.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.madrigalpharma.com/role/AccruedLiabilities 19 false false R20.htm 1020 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.madrigalpharma.com/role/StockBasedCompensation 20 false false R21.htm 1021 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies - Income Taxes (Details) Details 21 false false R22.htm 1022 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) Sheet http://www.madrigalpharma.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) Details 22 false false R23.htm 1023 - Disclosure - Liquidity and Uncertainties (Details) Sheet http://www.madrigalpharma.com/role/LiquidityAndUncertaintiesDetails Liquidity and Uncertainties (Details) Details http://www.madrigalpharma.com/role/LiquidityAndUncertainties 23 false false R24.htm 1024 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) Sheet http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesDetails Cash, Cash Equivalents and Marketable Securities (Details) Details http://www.madrigalpharma.com/role/CashCashEquivalentsAndMarketableSecuritiesTables 24 false false R25.htm 1025 - Disclosure - Accrued Liabilities (Details) Sheet http://www.madrigalpharma.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.madrigalpharma.com/role/AccruedLiabilitiesTables 25 false false R26.htm 1026 - Disclosure - Stockholders' Equity - Common Stock (Details) Sheet http://www.madrigalpharma.com/role/StockholdersEquityCommonStockDetails Stockholders' Equity - Common Stock (Details) Details 26 false false R27.htm 1027 - Disclosure - Stockholders' Equity - Preferred Stock (Details) Sheet http://www.madrigalpharma.com/role/StockholdersEquityPreferredStockDetails Stockholders' Equity - Preferred Stock (Details) Details 27 false false R28.htm 1028 - Disclosure - Stock-based Compensation - Stock Option (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationStockOptionDetails Stock-based Compensation - Stock Option (Details) Details 28 false false R29.htm 1029 - Disclosure - Stock-based Compensation - Expense (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation - Expense (Details) Details 29 false false R30.htm 1030 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details) Sheet http://www.madrigalpharma.com/role/StockBasedCompensationUnrecognizedExpenseDetails Stock-based Compensation - Unrecognized Expense (Details) Details 30 false false R31.htm 1031 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.madrigalpharma.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.madrigalpharma.com/role/CommitmentsAndContingencies 31 false false All Reports Book All Reports d848605d10q.htm d848605dex311.htm d848605dex312.htm d848605dex321.htm mdgl-20200331.xsd mdgl-20200331_cal.xml mdgl-20200331_def.xml mdgl-20200331_lab.xml mdgl-20200331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true

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end XML 40 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Statement of Comprehensive Income [Abstract]    
Net Loss $ (36,135) $ (15,080)
Other comprehensive income (loss):    
Unrealized gain on available-for-sale securities 199 497
Comprehensive loss $ (35,936) $ (14,583)